Cancer Journal

Overview

publication venue for

• Initial chemotherapy dose reductions and subsequent treatment delivery in stage I-IIIA breast cancer..  132. 2026
• Circulating tumor DNA informs clinical practice in patients with recurrent/metastatic gastroesophageal cancers..  132. 2026
• Chronic myelomonocytic leukemia in the young (aged 50 years and younger): Divergent clinical and molecular characteristics from the elderly..  131. 2025
• The impact of focused federal initiatives on pediatric cancer research..  131. 2025
• Cost-effectiveness of office-based, magnetic resonance imaging-guided transperineal versus transrectal prostate biopsy: An economic analysis of the PREVENT trial..  131. 2025
• Lobular breast cancer statistics, 2025..  131. 2025
• Overall side-effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatments..  131 Suppl 2. 2025
• Medical marijuana policies, opioid prescriptions, and adverse events among patients undergoing cancer resection surgery..  131. 2025
• Prognostic value of patient-reported depression in women with hormone-responsive early breast cancer in TEXT and SOFT..  131. 2025
• The American Cancer Society National Lung Cancer Roundtable strategic plan: Tobacco treatment in the context of lung cancer screening..  131. 2025
• Defining concepts in cancer survivorship..  131. 2025
• In vitro fertilization with cryopreserved oocytes or embryos after cancer: The role of gestational carriers..  131. 2025
• Health literacy and all-cause mortality among cancer patients..  131. 2025
• Prevalence of carotid ultrasound screening in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study..  131. 2024
• Breastfeeding experiences among young breast cancer survivors: A survey study..  131. 2024
• Role of primary care in opioid prescribing for older head and neck cancer survivors..  130. 2024
• Considering screening for hereditary cancer syndromes at the time of obstetrical prenatal carrier screening..  130. 2024
• Association of clonal hematopoiesis and mosaic chromosomal alterations with solid malignancy incidence and mortality..  130. 2024
• Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: Analysis of the phase 3 VISION trial..  130. 2024
• Insulin resistance during androgen deprivation therapy in men with prostate cancer..  130. 2024
• Breast cancer incidence and mortality by metabolic syndrome and obesity: The Women's Health Initiative..  130. 2024
• Prognosis and risk of suicide after cancer diagnosis..  130. 2023
• Alliance A151945: Accrual and characteristics of adolescent and young adult patients in Alliance trials from 2000 to 2017..  130. 2023
• Pathogenic germline variants in patients with endometrial cancer of diverse ancestry..  130. 2023
• Conception and pregnancy among women with a live birth after breast cancer treatment: A survey study of young breast cancer survivors..  130. 2023
• Risk model-based management for second primary lung cancer among lung cancer survivors through a validated risk prediction model..  130. 2023
• Genomic ancestry in kidney cancer: Correlations with clinical and molecular features..  130. 2023
• Ototoxicity associated with high-dose carboplatin for patients with previously treated germ cell tumors..  129. 2023
• Mammography screening beliefs and barriers through the lens of Black women during the COVID-19 pandemic..  129. 2023
• Determinants of overall survival in patients with metastatic uveal melanoma..  129. 2023
• Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG-ACRIN analysis..  129. 2023
• Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial..  129. 2023
• Effects of an educational physical activity intervention in young women with newly diagnosed breast cancer: Findings from the Young and Strong Study..  129. 2023
• The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real-world, multicenter, retrospective study..  129. 2023
• The clinical value of progesterone receptor expression in luminal breast cancer: A study of a large cohort with long-term follow-up..  129. 2023
• What happens in the long term: Uptake of cancer surveillance and prevention strategies among at-risk relatives with pathogenic variants detected via cascade testing..  128. 2022
• Patient outcomes following implementation of an enhanced recovery after surgery pathway for patients with metastatic spine tumors..  128. 2022
• Disparities in cancer genetics care by race/ethnicity among pan-cancer patients with pathogenic germline variants..  128. 2022
• Risk and tropism of central nervous system (CNS) metastases in patients with stage II and III cutaneous melanoma..  128. 2022
• Disparities in curative treatments and outcomes for early stage intrahepatic cholangiocarcinoma in the United States..  128. 2022
• Association between immigrant status and advanced cancer patients' location and quality of death..  128. 2022
• Body weight changes and associated predictors in a prospective cohort of young breast cancer survivors..  128. 2022
• "Is it cancer or not?" A qualitative exploration of survivor concerns surrounding the diagnosis and treatment of ductal carcinoma in situ..  128. 2022
• Transoral robotic surgery adoption and safety in treatment of oropharyngeal cancers..  128. 2021
• Have urinary function outcomes after radical prostatectomy improved over the past decade?.  128. 2021
• Trajectories of fear of cancer recurrence in young breast cancer survivors..  128. 2021
• Identifying and describing cancer survivors: Implications for cancer survivorship research and clinical care..  128. 2021
• Social determinants of health and cancer mortality in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study..  128. 2021
• Economic distress, financial toxicity, and medical cost-coping in young adult cancer survivors during the COVID-19 pandemic: Findings from an online sample..  127. 2021
• Weight loss does not decrease risk of breast cancer-related arm lymphedema..  127. 2021
• Treatment patterns and survival in patients with early-onset pancreatic cancer..  127. 2021
• Disparities in magnetic resonance imaging of the prostate for traditionally underserved patients with prostate cancer..  127. 2021
• Financial toxicity, mental health, and gynecologic cancer treatment: The effect of the COVID-19 pandemic among low-income women in New York City..  127. 2021
• Impact of fertility concerns on endocrine therapy decisions in young breast cancer survivors..  127. 2021
• Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2)..  127. 2021
• Outcome of T-cell-replete haploidentical stem cell transplantation improves with time in adults with acute lymphoblastic leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation..  127. 2021
• Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies..  127. 2021
• Racial disparities in patients with coronavirus disease 2019 infection and gynecologic malignancy..  127. 2020
• Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers..  127. 2020
• Pregnancy after breast cancer: Results from a prospective cohort of young women with breast cancer..  127. 2020
• Clinical implications of drug-induced liver injury in early-phase oncology clinical trials..  126. 2020
• Development and validation of a Surgical Prioritization and Ranking Tool and Navigation Aid for Head and Neck Cancer (SPARTAN-HN) in a scarce resource setting: Response to the COVID-19 pandemic..  126. 2020
• A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma..  126. 2020
• Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes..  126. 2020
• Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver..  126. 2020
• The 3 Bs of cancer care amid the COVID-19 pandemic crisis: "Be safe, be smart, be kind"-A multidisciplinary approach increasing the use of radiation and embracing telemedicine for head and neck cancer..  126. 2020
• Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer..  126. 2020
• Changes in prostate-specific antigen at the time of prostate cancer diagnosis after Medicaid expansion in young men..  126. 2020
• 11p15.5 epimutations in children with Wilms tumor and hepatoblastoma detected in peripheral blood..  126. 2020
• Effects of acupuncture versus cognitive behavioral therapy on cognitive function in cancer survivors with insomnia: A secondary analysis of a randomized clinical trial..  126. 2020
• Impact of prebiopsy magnetic resonance imaging on biopsy and radical prostatectomy grade concordance..  126. 2020
• Differences in ambulatory care fragmentation between cancer survivors and noncancer controls..  126. 2020
• Distant metastasis of salivary gland cancer: Incidence, management, and outcomes..  126. 2020
• Outcomes and toxicities of definitive radiotherapy and reirradiation using 3-dimensional conformal or intensity-modulated (pencil beam) proton therapy for patients with nasal cavity and paranasal sinus malignancies..  126. 2020
• Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings..  126. 2020
• Diabetes care management patterns before and after a cancer diagnosis: A SEER-Medicare matched cohort study..  126. 2020
• Physician and facility drivers of spending variation in locoregional prostate cancer..  126. 2020
• Genomic and clinical characterization of stromal infiltration markers in prostate cancer..  126. 2020
• The experience of hearing loss in adult survivors of childhood and young adult cancer: A qualitative study..  126. 2020
• Human papillomavirus and survival of patients with sinonasal squamous cell carcinoma..  126. 2019
• Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway..  126. 2019
• Pretreatment peripheral blood leukocytes are independent predictors of survival in oral cavity cancer..  126. 2019
• Prospective development of a patient-reported outcomes instrument for desmoid tumors or aggressive fibromatosis..  126. 2019
• "My doctor says the cancer is worse, but I believe in miracles"-When religious belief in miracles diminishes the impact of news of cancer progression on change in prognostic understanding..  126. 2019
• Barriers and facilitators of risk-based health care for adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study..  126. 2019
• Is screening for psychosocial risk factors associated with mental health care in older adults with cancer undergoing surgery?.  126. 2019
• Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer..  126. 2019
• Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network..  126. 2019
• Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin..  125. 2019
• Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers..  125. 2019
• Obesity and breast cancer screening: Cross-sectional survey results from the behavioral risk factor surveillance system..  125. 2019
• Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma..  125. 2019
• Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer..  125. 2019
• Association between advanced cancer patient-caregiver agreement regarding prognosis and hospice enrollment..  125. 2019
• Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer..  125. 2019
• The impact of frequent cystoscopy on surgical care and cancer outcomes among patients with low-risk, non-muscle-invasive bladder cancer..  125. 2019
• Impact of exercise on psychological burden in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study..  125. 2019
• A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas..  125. 2019
• Patient-centered engagement and symptom/toxicity monitoring in the new era of tumor next-generation sequencing and immunotherapy: The OncoTool and OncoPRO platforms..  125. 2019
• Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (¹⁷⁷ Lu-J591) for metastatic castration-resistant prostate cancer..  125. 2019
• A scale to assess religious beliefs in end-of-life medical care..  125. 2019
• A randomized study to improve care for young women with breast cancer at community and academic medical oncology practices in the United States: The Young and Strong study..  125. 2019
• The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study..  125. 2019
• A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma..  125. 2019
• Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes..  125. 2019
• Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?.  125. 2019
• Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes..  125. 2018
• Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy..  125. 2018
• Survival, local control, and health-related quality of life in patients with oligometastatic and polymetastatic spinal tumors: A multicenter, international study..  125. 2018
• Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center..  125. 2018
• Regional differences in gallbladder cancer pathogenesis: Insights from a multi-institutional comparison of tumor mutations..  125. 2018
• Efficacy of a survivorship-focused consultation versus a time-controlled rehabilitation consultation in patients with lymphoma: A cluster randomized controlled trial..  124. 2018
• Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions..  124. 2018
• Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer..  124. 2018
• The intersection of financial toxicity and family building in young adult cancer survivors..  124. 2018
• Individual meaning-centered psychotherapy for the treatment of psychological and existential distress: A randomized controlled trial in patients with advanced cancer..  124. 2018
• Symptom and function profiles of men with localized prostate cancer..  124. 2018
• Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure..  124. 2018
• Feasibility, safety, and efficacy of aerobic training in pretreated patients with metastatic breast cancer: A randomized controlled trial..  124. 2018
• Increased resource use in men with metastatic prostate cancer does not result in improved survival or quality of care at the end of life..  124. 2018
• Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA..  124. 2018
• Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer..  124. 2018
• Nonsurgical premature menopause and reproductive implications in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study..  124. 2018
• Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma..  124. 2018
• Bone biopsy protocol for advanced prostate cancer in the era of precision medicine..  124. 2017
• Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia..  124. 2017
• Management of precancerous anal intraepithelial lesions in human immunodeficiency virus-positive men who have sex with men: Clinical effectiveness and cost-effectiveness..  123. 2017
• Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases..  124. 2017
• Comparison of recommendations for screening mammography using CISNET models..  123. 2017
• A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma..  123. 2017
• Preventable and mitigable adverse events in cancer care: Measuring risk and harm across the continuum..  123. 2017
• Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer..  123. 2017
• Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer..  123. 2017
• Incidence of hematologic malignancy and cause-specific mortality in the Women's Health Initiative randomized controlled trial of calcium and vitamin D supplementation..  123. 2017
• Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics..  123. 2017
• The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis..  123. 2017
• Androgen receptor-positive, triple-negative breast cancer..  123. 2017
• Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation..  123. 2017
• A comprehensive comparative analysis of treatment modalities for sinonasal malignancies..  123. 2017
• Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinoma..  123. 2017
• Are there patients with T1 to T2, lymph node-negative breast cancer who are "high-risk" for locoregional disease recurrence?.  123. 2017
• Longitudinal follow-up of adult survivors of Ewing sarcoma: A report from the Childhood Cancer Survivor Study..  123. 2017
• Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel..  123. 2017
• Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma..  123. 2017
• Association between lymph node yield and survival among patients undergoing radical nephroureterectomy for urothelial carcinoma of the upper tract..  123. 2017
• Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation..  123. 2017
• Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes..  123. 2017
• A pilot randomized controlled trial of cognitive bias modification to reduce fear of breast cancer recurrence..  123. 2017
• Impact of concomitant chemoradiation on survival for patients with T1-2N1 head and neck cancer..  123. 2016
• The toxicity and efficacy of concomitant chemoradiotherapy in patients aged 70 years and older with oropharyngeal carcinoma in the intensity-modulated radiotherapy era..  123. 2016
• Clinical and genetic determinants of ovarian metastases from colorectal cancer..  123. 2016
• Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases..  123. 2016
• Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)..  123. 2016
• A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck..  122. 2016
• Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial..  123. 2016
• A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)..  122. 2016
• Correlating mammographic and pathologic findings in clinical decision support using natural language processing and data mining methods..  123. 2016
• Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies..  122. 2016
• The efficacy of anti-PD-1 agents in acral and mucosal melanoma..  122. 2016
• Frailty as determined by a comprehensive geriatric assessment-derived deficit-accumulation index in older patients with cancer who receive chemotherapy..  122. 2016
• Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up..  123. 2016
• Receipt of vaginal brachytherapy is associated with improved survival in women with stage I endometrioid adenocarcinoma of the uterus: A National Cancer Data Base study..  122. 2016
• White adipose tissue inflammation and cancer-specific survival in patients with squamous cell carcinoma of the oral tongue..  122. 2016
• Genomic characterization of response to chemoradiation in urothelial bladder cancer..  122. 2016
• Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis..  122. 2016
• Long-term trajectories of self-reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance)..  122. 2016
• Breast intraductal papillomas without atypia in radiologic-pathologic concordant core-needle biopsies: Rate of upgrade to carcinoma at excision..  122. 2016
• Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer..  122. 2016
• Second-opinion interpretations of neuroimaging studies by oncologic neuroradiologists can help reduce errors in cancer care..  122. 2016
• Young adult female cancer survivors' unmet information needs and reproductive concerns contribute to decisional conflict regarding posttreatment fertility preservation..  122. 2016
• Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508)..  122. 2016
• Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma..  122. 2016
• Accuracy of advanced cancer patients' life expectancy estimates: The role of race and source of life expectancy information..  122. 2016
• Cognitive testing of tobacco use items for administration to patients with cancer and cancer survivors in clinical research..  122. 2016
• Impact of end-of-life discussions on the reduction of Latino/non-Latino disparities in do-not-resuscitate order completion..  122. 2016
• Increase in primary surgical treatment of T1 and T2 oropharyngeal squamous cell carcinoma and rates of adverse pathologic features: National Cancer Data Base..  122. 2016
• Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program..  122. 2016
• Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status..  122. 2016
• Preoperative experience for public hospital patients with gynecologic cancer: Do structural barriers widen the gap?.  122. 2016
• Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma..  122. 2016
• Chronic medical conditions in adult survivors of retinoblastoma: Results of the Retinoblastoma Survivor Study..  122. 2016
• Impact of vision loss among survivors of childhood central nervous system astroglial tumors..  122. 2016
• Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies..  122. 2016
• Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium..  122. 2015
• Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone..  122. 2015
• The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents..  122. 2015
• Breast cancer risk by extent and type of atypical hyperplasia: An update from the Nurses' Health Studies..  122. 2015
• Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma..  122. 2015
• Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer..  122. 2015
• The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: Analysis of the National Cancer Data Base..  122. 2015
• Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma..  122. 2015
• Identification of germline genetic mutations in patients with pancreatic cancer..  121. 2015
• Comorbidities, smoking status, and life expectancy among individuals eligible for lung cancer screening..  121. 2015
• Extent of resection and overall survival for patients with atypical and malignant meningioma..  121. 2015
• Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancer..  121. 2015
• Cost-effectiveness analysis of papillary thyroid cancer surveillance..  121. 2015
• Risk stratification in patients with advanced-stage breast cancer by pretreatment [(18) F]FDG PET/CT..  121. 2015
• Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications..  121. 2015
• Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib..  121. 2015
• Disparities in survival by insurance status in patients with Hodgkin lymphoma..  121. 2015
• The lasting impact of the therapeutic alliance: Patient-oncologist alliance as a predictor of caregiver bereavement adjustment..  121. 2015
• Do attitudes and beliefs regarding complementary and alternative medicine impact its use among patients with cancer? A cross-sectional survey..  121. 2015
• Male-female patient differences in the association between end-of-life discussions and receipt of intensive care near death..  121. 2015
• Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas..  121. 2015
• Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy..  121. 2015
• Treatment-related toxicities in older adults with head and neck cancer: A population-based analysis..  121. 2015
• Increasing diagnosis of subclinical thyroid cancers leads to spurious improvements in survival rates..  121. 2015
• Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma..  121. 2014
• The effects of cancer and racial disparities in health-related quality of life among older Americans: a case-control, population-based study..  121. 2014
• Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma..  121. 2014
• RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer..  121. 2014
• Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project..  121. 2014
• Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)..  121. 2014
• Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium..  121. 2014
• A mixed-methods examination of communication between oncologists and primary care providers among primary care physicians in underserved communities..  121. 2014
• Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium..  121. 2014
• Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: a report from the Children's Oncology Group..  121. 2014
• Electronic cigarette use among patients with cancer: characteristics of electronic cigarette users and their smoking cessation outcomes..  120. 2014
• Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients..  121. 2014
• Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma..  121. 2014
• KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases..  120. 2014
• Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients..  121. 2014
• End-of-life treatment preferences: a key to reducing ethnic/racial disparities in advance care planning?.  120. 2014
• US lung cancer trends by histologic type..  120. 2014
• Does adjuvant radiotherapy benefit patients with diffuse-type gastric cancer? Results from the Surveillance, Epidemiology, and End Results database..  120. 2014
• Suicidal ideation in prostate cancer survivors: understanding the role of physical and psychological health outcomes..  120. 2014
• Patient-oncologist alliance as protection against suicidal ideation in young adults with advanced cancer..  120. 2014
• Treatment-related amenorrhea and sexual functioning in young breast cancer survivors..  120. 2014
• Infections among long-term survivors of childhood and adolescent cancer: a report from the Childhood Cancer Survivor Study..  120. 2014
• Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy..  120. 2014
• A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study..  120. 2014
• Disease and treatment characteristics do not predict symptom occurrence profiles in oncology outpatients receiving chemotherapy..  120. 2014
• Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project..  120. 2014
• BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer..  120. 2014
• Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network..  120. 2014
• Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era..  120. 2014
• The prognosis of N2b and N2c lymph node disease in oral squamous cell carcinoma is determined by the number of metastatic lymph nodes rather than laterality: evidence to support a revision of the American Joint Committee on Cancer staging system..  120. 2014
• Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program..  120. 2014
• Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma..  120. 2014
• Causes of death in long-term survivors of head and neck cancer..  120. 2014
• Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period..  120. 2014
• Impact of obesity on the survival of patients with early-stage squamous cell carcinoma of the oral tongue..  120. 2014
• Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710..  120. 2014
• Distribution and trends of hematology and oncology research in Latin America: A decade of uncertainty..  120. 2013
• Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms..  120. 2013
• An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer..  120. 2013
• Pain palliation measurement in cancer clinical trials: the US Food and Drug Administration perspective..  120. 2013
• The end-of-life experience: modifiable predictors of caregivers' bereavement adjustment..  120. 2013
• Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma..  120. 2013
• Reducing time-to-treatment in underserved Latinas with breast cancer: the Six Cities Study..  120. 2013
• Breast cancer presentation and diagnostic delays in young women..  120. 2013
• Nomograms for preoperative prediction of prognosis in patients with oral cavity squamous cell carcinoma..  120. 2013
• Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group..  120. 2013
• Suicide ideation and associated mortality in adult survivors of childhood cancer..  120. 2013
• TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial..  119. 2013
• Improvement in survival of patients with oral cavity squamous cell carcinoma: An international collaborative study..  119. 2013
• Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer..  119. 2013
• Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials..  119. 2013
• Changes in the availability of screening mammography, 2000-2010..  119. 2013
• Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project..  119. 2013
• Addressing overtreatment in breast cancer: The doctors' dilemma..  119. 2013
• Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience..  119. 2013
• The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance)..  119. 2013
• Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer..  119. 2013
• Intensity-modulated radiotherapy (IMRT) in pediatric low-grade glioma..  119. 2013
• Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody..  119. 2013
• Cost-effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer..  119. 2013
• Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older..  119. 2013
• Health care-associated infections after major cancer surgery: temporal trends, patterns of care, and effect on mortality..  119. 2013
• External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma..  119. 2013
• A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer..  119. 2013
• Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005)..  119. 2013
• A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas..  119. 2013
• Preoperative BRAF(V600E) mutation screening is unlikely to alter initial surgical treatment of patients with indeterminate thyroid nodules: a prospective case series of 960 patients..  119. 2012
• Examining whether lung screening changes risk perceptions: National Lung Screening Trial participants at 1-year follow-up..  119. 2012
• Navigating Latinas with breast screen abnormalities to diagnosis: the Six Cities Study..  119. 2012
• Implementing a breast cancer registry and treatment plan/summary program in clinical practice: a pilot program..  119. 2012
• Patient perspectives on breast cancer treatment plan and summary documents in community oncology care: a pilot program..  119. 2012
• Long-term regional control and survival in patients with "low-risk," early stage oral tongue cancer managed by partial glossectomy and neck dissection without postoperative radiation: the importance of tumor thickness..  119. 2012
• Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer..  119. 2012
• ABVD alone and a PET scan complete remission negates the need for radiologic surveillance in early-stage, nonbulky Hodgkin lymphoma..  119. 2012
• Classic lobular carcinoma in situ and atypical lobular hyperplasia at percutaneous breast core biopsy: outcomes of prospective excision..  119. 2012
• Gene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancer..  119. 2012
• Thyroid transcription factor-1 expression is an independent predictor of recurrence and correlates with the IASLC/ATS/ERS histologic classification in patients with stage I lung adenocarcinoma..  119. 2012
• Percutaneous image-guided cryoablation of painful metastases involving bone: multicenter trial..  119. 2012
• Elderly patients with colon cancer have unique tumor characteristics and poor survival..  119. 2012
• BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer..  119. 2012
• Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer..  118. 2012
• Toll-like receptor-4 signaling in mantle cell lymphoma: effects on tumor growth and immune evasion..  119. 2012
• Determining the impact of US mammography screening guidelines on patient survival in a predominantly African American population treated in a public hospital during 2008..  119. 2012
• Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas..  119. 2012
• Incorporating information regarding preimplantation genetic diagnosis into discussions concerning testing and risk management for BRCA1/2 mutations: a qualitative study of patient preferences..  118. 2012
• Who should be included in a clinical trial of screening for bladder cancer?: a decision analysis of data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial..  119. 2012
• Percutaneous endoscopic gastrostomy in oropharyngeal cancer patients treated with intensity-modulated radiotherapy with concurrent chemotherapy..  118. 2012
• A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer..  118. 2012
• Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics..  118. 2012
• Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma..  118. 2012
• Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas..  118. 2012
• Fractures among long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study..  118. 2012
• Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial..  118. 2012
• A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer..  118. 2012
• Measuring psychosocial distress and parenting concerns among adults with cancer: the Parenting Concerns Questionnaire..  118. 2012
• Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer..  118. 2012
• Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older..  118. 2012
• Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer..  118. 2012
• Involvement of epidermal growth factor receptor overexpression in the promotion of breast cancer brain metastasis..  118. 2012
• A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors..  118. 2012
• Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors..  118. 2012
• A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer..  118. 2012
• Costs and trends in pancreatic cancer treatment..  118. 2012
• Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy..  118. 2012
• Leapfrog volume thresholds and perioperative complications after radical prostatectomy..  118. 2012
• Psychometric validation of the Female Sexual Function Index (FSFI) in cancer survivors..  118. 2012
• Use of complementary medications among older adults with cancer..  118. 2012
• Disparities in access to care at high-volume institutions for uro-oncologic procedures..  118. 2012
• Augmenting advance care planning in poor prognosis cancer with a video decision aid: a preintervention-postintervention study..  118. 2012
• Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group..  118. 2012
• Single versus multiple primary melanomas: old questions and new answers..  118. 2012
• Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782..  118. 2011
• Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma..  118. 2011
• Selective radiotherapy for the treatment of head and neck Merkel cell carcinoma..  118. 2011
• Increasing incidence of enteropathy-associated T-cell lymphoma in the United States, 1973-2008..  118. 2011
• Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer..  118. 2011
• Current or recent pregnancy is associated with adverse pathologic features but not impaired survival in early breast cancer..  118. 2011
• Durable remission with salvage second autotransplants in patients with multiple myeloma..  118. 2011
• Young women with family history of breast cancer and their risk factors for benign breast disease..  118. 2011
• Androgen deprivation and thromboembolic events in men with prostate cancer..  118. 2011
• Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study..  118. 2011
• Recurrence after complete resection and selective use of adjuvant therapy for stage I through III Merkel cell carcinoma..  118. 2011
• Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas..  118. 2011
• Costs of medical care after open or minimally invasive prostate cancer surgery: a population-based analysis..  118. 2011
• Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma..  118. 2011
• Patient satisfaction and health-related quality of life after autologous tissue breast reconstruction: a prospective analysis of early postoperative outcomes..  118. 2011
• 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response..  118. 2011
• Impact of race on survival in patients with clinically nonmetastatic prostate cancer who deferred primary treatment..  118. 2011
• A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer..  118. 2011
• Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database..  118. 2011
• Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer..  118. 2011
• Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer..  118. 2011
• The use of bevacizumab among women with metastatic breast cancer: a survey on clinical practice and the ongoing controversy..  118. 2011
• Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study..  118. 2011
• Long-term outcomes in breast cancer patients undergoing immediate 2-stage expander/implant reconstruction and postmastectomy radiation..  118. 2011
• Improvement of racial disparities with respect to the utilization of minimally invasive radical prostatectomy in the United States..  118. 2011
• Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma..  118. 2011
• A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid..  118. 2011
• Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer..  118. 2011
• Radiation field design and regional control in sentinel lymph node-positive breast cancer patients with omission of axillary dissection..  118. 2011
• Morbidity and mortality of radical prostatectomy differs by insurance status..  118. 2011
• Return to work in low-income Latina and non-Latina white breast cancer survivors: a 3-year longitudinal study..  118. 2011
• Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis..  118. 2011
• Inappropriate utilization of radiographic imaging in men with newly diagnosed prostate cancer in the United States..  118. 2011
• Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design..  118. 2011
• A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma..  118. 2011
• Prospective impact of tumor grade assessment in biopsies on tumor stage and prognostic grouping in gastroesophageal adenocarcinoma: relevance of the seventh edition American Joint Committee on Cancer Staging Manual revision..  118. 2011
• Early stage squamous cell cancer of the oral tongue--clinicopathologic features affecting outcome..  118. 2011
• The enigma of myxofibrosarcoma of the extremity..  118. 2011
• Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303)..  118. 2011
• Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome..  117. 2011
• Adjuvant chemotherapy improves survival in patients with American Joint Committee on Cancer stage II colon cancer..  117. 2011
• Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer..  118. 2011
• Research challenges in adolescent and young adult cancer survivor research..  117. 2011
• The cancer is over, now what?: Understanding risk, changing outcomes..  117. 2011
• A Surveillance, Epidemiology, and End Results analysis of small cell carcinoma of the bladder: epidemiology, prognostic variables, and treatment trends..  117. 2011
• Support of cancer patients' spiritual needs and associations with medical care costs at the end of life..  117. 2011
• Patients rate physician communication about lung cancer..  117. 2011
• Reirradiation for recurrent medulloblastoma..  117. 2011
• Reverse stage shift at a tertiary care center: escalating risk in men undergoing radical prostatectomy..  117. 2011
• Soft tissue sarcoma diagnosed subsequent to lymphoma is associated with prior radiotherapy and decreased survival..  117. 2011
• Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy..  117. 2011
• Temporal trends and predictors of pelvic lymph node dissection in open or minimally invasive radical prostatectomy..  117. 2011
• Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer..  117. 2011
• Racial disparities and socioeconomic status in men diagnosed with testicular germ cell tumors: a survival analysis..  117. 2011
• Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies..  117. 2011
• Utilization and expense of adjuvant cancer therapies following radical prostatectomy..  117. 2011
• Conditional survival predictions after surgery for patients with penile carcinoma..  117. 2011
• Prospective study of growth and development in older girls and risk of benign breast disease in young women..  117. 2011
• Local control comparison of adjuvant brachytherapy to intensity-modulated radiotherapy in primary high-grade sarcoma of the extremity..  117. 2011
• Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decision-curve analysis..  117. 2011
• Studying cancer in minorities: a look at the numbers..  117. 2011
• Clinical outcomes for patients with soft tissue sarcoma of the hand..  117. 2011
• Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study..  117. 2010
• Treatment of epidural spinal cord involvement from germ cell tumors with chemotherapy..  117. 2010
• Evaluation of lymph node counts in primary retroperitoneal lymph node dissection..  116. 2010
• A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus..  117. 2010
• Addition of pamidronate to chemotherapy for the treatment of osteosarcoma..  117. 2010
• Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival..  117. 2010
• Patient satisfaction with postmastectomy breast reconstruction: a comparison of saline and silicone implants..  116. 2010
• Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression..  117. 2010
• Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement..  117. 2010
• Evaluation of a breast cancer risk prediction model expanded to include category of prior benign breast disease lesion..  116. 2010
• Methylphenidate for fatigue in ambulatory men with prostate cancer..  116. 2010
• Expanding colorectal cancer screening among minority women..  117. 2010
• Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50..  117. 2010
• A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer..  117. 2010
• Twenty years of follow-up of survivors of childhood osteosarcoma: a report from the Childhood Cancer Survivor Study..  117. 2010
• Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience..  116. 2010
• Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography..  116. 2010
• Influence of patients' preferences and treatment site on cancer patients' end-of-life care..  116. 2010
• Craniofacial resection for malignant tumors involving the skull base in the elderly: an international collaborative study..  117. 2010
• Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma..  117. 2010
• A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography..  116. 2010
• Increasing incidence of rectal cancer in patients aged younger than 40 years: an analysis of the surveillance, epidemiology, and end results database..  116. 2010
• Local control after craniospinal irradiation, intensity-modulated radiotherapy boost, and chemotherapy in childhood medulloblastoma..  117. 2010
• Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors..  116. 2010
• Noninvasive imaging with thallium-201 scintigraphy may not correlate with survival in patients with osteosarcoma..  116. 2010
• A population-based competing-risks analysis of the survival of patients treated with radical cystectomy for bladder cancer..  117. 2010
• Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals..  116. 2010
• Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life..  116. 2010
• Evaluation of neoadjuvant therapy and histopathologic response in primary, high-grade retroperitoneal sarcomas using the sarcoma nomogram..  116. 2010
• Highly predictive survival nomogram after upper urinary tract urothelial carcinoma..  116. 2010
• Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I..  116. 2010
• The culture of faith and hope: patients' justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials..  116. 2010
• Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study..  116. 2010
• Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma..  116. 2010
• A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic score..  116. 2010
• A prospective evaluation of the durability of palliative interventions for patients with metastatic breast cancer..  116. 2010
• Detection of minimal residual disease in blood and bone marrow in early stage breast cancer..  116. 2010
• Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma..  116. 2010
• Clinical and pathologic factors that predict lymph node yield from surgical specimens in colorectal cancer: a population-based study..  116. 2010
• Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4..  116. 2010
• Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma..  116. 2010
• Novel targeted therapies in inflammatory breast cancer..  116. 2010
• Suberoylanilide hydroxamic acid blocks self-renewal and homotypic aggregation of inflammatory breast cancer spheroids..  116. 2010
• Trends in renal tumor surgery delivery within the United States..  116. 2010
• Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor)..  116. 2010
• Number of lymph nodes removed in sentinel lymph node-negative breast cancer patients is significantly related to patient age and tumor size: a new source of bias in morbidity assessment?.  116. 2010
• Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker..  116. 2010
• Anxiety disorders in advanced cancer patients: correlates and predictors of end-of-life outcomes..  116. 2010
• Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas..  116. 2010
• Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival..  116. 2010
• Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy..  116. 2010
• Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099..  116. 2010
• Stage IV breast cancer in the era of targeted therapy: does surgery of the primary tumor matter?.  116. 2010
• A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer..  116. 2010
• Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer..  116. 2010
• Impact of smoking on patients with stage III colon cancer: results from Cancer and Leukemia Group B 89803..  116. 2010
• Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer..  116. 2010
• Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: a Gynecologic Oncology Group Study..  116. 2010
• Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign..  116. 2010
• Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation..  116. 2010
• Clinical utility of postchemoradiation endoscopic brush cytology and biopsy in predicting residual esophageal adenocarcinoma..  117. 2009
• Impact of radiation and chemotherapy on risk of dental abnormalities: a report from the Childhood Cancer Survivor Study..  115. 2009
• Lymph node density is a significant predictor of outcome in patients with oral cancer..  115. 2009
• Prognostic significance of lymph node invasion in patients with metastatic renal cell carcinoma: a population-based perspective..  115. 2009
• Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approach..  115. 2009
• Ethnic disparity in mortality after diagnosis of colorectal cancer among inner city minority New Yorkers..  115. 2009
• Identification of borderline thyroid tumors by gene expression array analysis..  115. 2009
• Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium..  115. 2009
• Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group..  115. 2009
• Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma..  115. 2009
• Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinoma..  115. 2009
• A comparison of outcomes from treating hepatocellular carcinoma by hepatic artery embolization in patients younger or older than 70 years..  115. 2009
• Image-guided ThinPrep Papanicolaou tests and cotesting with high-risk human papillomavirus in women aged 30 years and older in a low-risk private practice population..  117. 2009
• Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel: an analysis of Gynecologic Oncology Group trials..  115. 2009
• Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study..  115. 2009
• Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer..  115. 2009
• Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial..  115. 2009
• Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas: comparison on cell block, needle-core, and tissue block preparations..  117. 2009
• Measuring therapeutic alliance between oncologists and patients with advanced cancer: the Human Connection Scale..  115. 2009
• Targeting the urokinase plasminogen activator receptor with a monoclonal antibody impairs the growth of human colorectal cancer in the liver..  115. 2009
• Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer..  115. 2009
• EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer..  115. 2009
• Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma..  115. 2009
• Abnormal timing of menarche in survivors of central nervous system tumors: A report from the Childhood Cancer Survivor Study..  115. 2009
• Clinical and pathologic prognostic features in acinic cell carcinoma of the parotid gland..  115. 2009
• Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia..  115. 2009
• Lobule type and subsequent breast cancer risk: results from the Nurses' Health Studies..  115. 2009
• Radical versus partial nephrectomy: effect on overall and noncancer mortality..  115. 2009
• Surveillance of urothelial carcinoma: stage and grade migration, 1993-2005 and survival trends, 1993-2000..  115. 2009
• Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy..  115. 2009
• Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration..  115. 2009
• Postmastectomy radiotherapy for breast cancer: patterns, correlates, communication, and insights into the decision process..  115. 2009
• Health-related quality of life in long-term breast cancer survivors: differences by adjuvant chemotherapy dose in Cancer and Leukemia Group B study 8541..  115. 2009
• Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer..  115. 2009
• Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy..  115. 2009
• EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer..  117. 2009
• Reflex UroVysion testing in suspicious urine cytology cases..  117. 2009
• A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma..  115. 2009
• Mental health, treatment preferences, advance care planning, location, and quality of death in advanced cancer patients with dependent children..  115. 2009
• Novel agents in myeloma: an exciting saga..  115. 2009
• Survival of distinct Asian groups among colorectal cancer cases in California..  115. 2009
• Influence of compartmental involvement on the patterns of morbidity in soft tissue sarcoma of the thigh..  115. 2009
• Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors..  115. 2009
• Comparison of ProEx C with p16INK4a and Ki-67 immunohistochemical staining of cell blocks prepared from residual liquid-based cervicovaginal material: a pilot study..  114. 2008
• Changes in the presentation of nodular and superficial spreading melanomas over 35 years..  113. 2008
• Extraskeletal myxoid chondrosarcoma: a retrospective review from 2 referral centers emphasizing long-term outcomes with surgery and chemotherapy..  113. 2008
• A prospective feasibility trial to determine the significance of the sentinel node gradient in breast cancer: a predictor of nodal metastasis location..  113. 2008
• Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma..  113. 2008
• A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience..  113. 2008
• Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia..  113. 2008
• Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?.  113. 2008
• Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma..  113. 2008
• Serum interleukin-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation..  113. 2008
• Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma..  113. 2008
• Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer..  113. 2008
• Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of Babel..  113. 2008
• Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme..  113. 2008
• Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy..  113. 2008
• Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004..  113. 2008
• Cancer screening practices of adult survivors of retinoblastoma at risk of second cancers..  113. 2008
• High mobility group AT-hook 1 (HMGA1) is an independent prognostic factor and novel therapeutic target in pancreatic adenocarcinoma..  113. 2008
• Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms..  113. 2008
• Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma..  113. 2008
• Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation..  113. 2008
• Survival rates after resection for localized kidney cancer: 1989 to 2004..  113. 2008
• Impact of the more restrictive definition of atypical squamous cells introduced by the 2001 Bethesda System on the sensitivity and specificity of the Papanicolaou test: a 5-year follow-up study of Papanicolaou tests originally interpreted as ASCUS, reclassified according to Bethesda 2001 criteria..  114. 2008
• Cervical cancer in patients infected with the human immunodeficiency virus..  112. 2008
• Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy..  112. 2008
• Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer..  112. 2008
• Long-term outcomes in extremity soft tissue sarcoma after a pathologically negative re-resection and without radiotherapy..  112. 2008
• Prognostic factors for patients with stage IV epithelial ovarian cancer receiving intraperitoneal chemotherapy after second-look assessment: results of long-term follow-up..  112. 2008
• Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer..  112. 2008
• Peace, Equanimity, and Acceptance in the Cancer Experience (PEACE): validation of a scale to assess acceptance and struggle with terminal illness..  112. 2008
• Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma..  112. 2008
• Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy..  112. 2008
• Experience with 31 sentinel lymph node biopsies for sarcomas and carcinomas in pediatric patients..  112. 2008
• Prognostic significance of HER-2 status in women with inflammatory breast cancer..  112. 2008
• Twenty years of follow-up among survivors of childhood and young adult acute myeloid leukemia: a report from the Childhood Cancer Survivor Study..  112. 2008
• Diagnostic challenges of metastatic spindle cell melanoma on fine-needle aspiration specimens..  114. 2008
• Negative influence of changing biopsy practice patterns on the predictive value of prostate-specific antigen for cancer detection on prostate biopsy..  112. 2008
• Proxy perspectives regarding end-of-life care for persons with cancer..  112. 2008
• Changing indications for surgery in patients with stage IV breast cancer: a current perspective..  112. 2008
• Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation..  112. 2008
• Symptom burden after autologous stem cell transplantation for multiple myeloma..  112. 2008
• Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas..  112. 2008
• Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium..  112. 2008
• Cytologic findings after fertility-sparing radical trachelectomy..  114. 2008
• The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor..  112. 2008
• Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST)..  112. 2008
• Understanding the impact of breast reconstruction on the surgical decision-making process for breast cancer..  112. 2008
• Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy..  112. 2008
• Bcl-6 predicts improved prognosis in primary central nervous system lymphoma..  112. 2008
• Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent..  112. 2008
• Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial..  110. 2007
• Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma..  110. 2007
• Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft-tissue sarcoma of the extremity : a retrospective analysis..  110. 2007
• Prognostic significance of synaptophysin in stage I of squamous carcinoma and adenocarcinoma of the lung..  110. 2007
• Spinal metastases from myxoid liposarcoma warrant screening with magnetic resonance imaging..  110. 2007
• Expression of granulocyte-colony-stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens: potential consequences of granulocyte-colony-stimulating factor administration..  110. 2007
• Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease..  110. 2007
• Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study..  110. 2007
• Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation..  110. 2007
• Patterns of treatment in older adults with primary central nervous system lymphoma..  110. 2007
• Analysis of prognostic factors in 146 patients with anterior skull base sarcoma: an international collaborative study..  110. 2007
• Role of radiologic imaging at the time of initial diagnosis of stage T1b-T3b melanoma..  110. 2007
• Liquid-based Papanicolaou test (SurePath) interpretations before histologic diagnosis of endometrial hyperplasias and carcinomas: study of 272 cases classified by the 2001 Bethesda system..  111. 2007
• Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer..  110. 2007
• Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer..  110. 2007
• Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity..  110. 2007
• Hepatic metastasectomy in children..  109. 2007
• Correlates of referral practices of general surgeons to plastic surgeons for mastectomy reconstruction..  109. 2007
• Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma..  109. 2007
• Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis..  109. 2007
• Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: children's Cancer Group (CCG) 7943..  109. 2007
• Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells..  109. 2007
• Management of primary liver sarcomas..  109. 2007
• Survivin expression is associated with bladder cancer presence, stage, progression, and mortality..  109. 2007
• Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome..  109. 2007
• Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy..  109. 2007
• Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors..  109. 2007
• Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function..  109. 2007
• EphA2 overexpression is associated with angiogenesis in ovarian cancer..  109. 2007
• Magnitude and laterality of breast cancer risk according to histologic type of atypical hyperplasia: results from the Nurses' Health Study..  109. 2007
• A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma..  107. 2006
• Distress, psychiatric syndromes, and impairment of function in women with newly diagnosed breast cancer..  107. 2006
• FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease..  107. 2006
• Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression..  107. 2006
• Treatment outcome for metastatic papillary renal cell carcinoma patients..  107. 2006
• Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed?.  107. 2006
• Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study..  107. 2006
• Significance of intraoperative ureteral evaluation at radical cystectomy for urothelial cancer..  107. 2006
• New York City's immigrant minorities. Reducing cancer health disparities..  107. 2006
• Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma..  107. 2006
• Early 18F-labeled fluoro-2-deoxy-D-glucose positron emission tomography scanning in the lymphomas: changing the paradigms of treatments?.  107. 2006
• Lysophosphatidic acid acyltransferase-beta (LPAAT-beta) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survival..  107. 2006
• Treatment algorithm for locally recurrent osteosarcoma based on local disease-free interval and the presence of lung metastasis..  107. 2006
• Treatment of metastatic sarcoma to the liver with bland embolization..  107. 2006
• Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity..  107. 2006
• The influence of family history on breast cancer risk in women with biopsy-confirmed benign breast disease: results from the Nurses' Health Study..  107. 2006
• A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach..  107. 2006
• A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer..  107. 2006
• Fine-needle aspiration cytology of mammary adenomyoepithelioma: a study of 12 patients..  108. 2006
• Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder..  107. 2006
• Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma..  107. 2006
• The effect of postprostatectomy external beam radiotherapy on quality of life: results from the Cancer of the Prostate Strategic Urologic Research Endeavor..  107. 2006
• Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue..  106. 2006
• Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patients..  106. 2006
• Selecting patients for breast-conserving therapy: the importance of lobular histology..  106. 2006
• Cancer-specific survival and predictors of prostate-specific antigen recurrence and survival in patients with seminal vesicle invasion after radical prostatectomy..  106. 2006
• Particle embolization of recurrent hepatocellular carcinoma after hepatectomy..  106. 2006
• Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma..  106. 2006
• Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa..  106. 2006
• Prognostic factors of recurrence in encapsulated Hurthle cell carcinoma of the thyroid gland: a clinicopathologic study of 50 cases..  106. 2006
• Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer..  106. 2006
• Outcome of patients with fibrolamellar hepatocellular carcinoma..  106. 2006
• Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients..  106. 2006
• Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with Stage IV melanoma..  106. 2006
• Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy..  106. 2006
• Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma..  106. 2006
• Are all melanomas the same? Spitzoid melanoma is a distinct subtype of melanoma..  106. 2006
• Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma..  106. 2006
• Cytokeratin 20 expression identifies a subtype of pancreatic adenocarcinoma with decreased overall survival..  106. 2006
• Does a delay between diagnosis and radical prostatectomy increase the risk of disease recurrence?.  106. 2006
• Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells..  106. 2006
• Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma..  106. 2006
• Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma..  106. 2006
• Psychiatric disorders and mental health service use in patients with advanced cancer: a report from the coping with cancer study..  104. 2005
• Correlates of breast reconstruction: results from a population-based study..  104. 2005
• Long-term outcomes of adult survivors of childhood cancer..  104. 2005
• Salvage temozolomide for prior temozolomide responders..  104. 2005
• Tobacco smoking, GSTP1 polymorphism, and bladder carcinoma..  104. 2005
• Trends in survival from primary central nervous system lymphoma, 1975-1999: a population-based analysis..  104. 2005
• Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma..  104. 2005
• Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma..  104. 2005
• Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience..  104. 2005
• Developing a cancer-specific geriatric assessment: a feasibility study..  104. 2005
• Outcome of partial hepatectomy for large (> 10 cm) hepatocellular carcinoma..  104. 2005
• Surgeon perspectives about local therapy for breast carcinoma..  104. 2005
• Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane..  104. 2005
• Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066..  104. 2005
• Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors..  104. 2005
• The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999..  104. 2005
• Significance of benign endometrial cells in papanicolaou tests from women aged >or=40 years..  105. 2005
• The utility of B72.3, carcinoembryonic antigen, and Leu M-1 in cell blocks: an adjunct to fine-needle aspiration diagnosis of bronchioloalveolar carcinoma of the lung..  105. 2005
• Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy..  104. 2005
• Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrence..  104. 2005
• Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy..  104. 2005
• Ovarian carcinoma screening in women at intermediate risk: impact on quality of life and need for invasive follow-up..  104. 2005
• Frequency of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters..  103. 2005
• Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study..  103. 2005
• High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib..  103. 2005
• Body mass index is weakly associated with, and not a helpful predictor of, disease progression in men with clinically localized prostate carcinoma treated with radical prostatectomy..  103. 2005
• Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial..  103. 2005
• Postoperative complications of salvage total laryngectomy..  103. 2005
• Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma..  103. 2005
• Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study..  103. 2005
• Body mass index in long-term adult survivors of childhood cancer: a report of the Childhood Cancer Survivor Study..  103. 2005
• A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas..  103. 2005
• The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma..  103. 2005
• Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma..  103. 2005
• Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma..  103. 2005
• Validation of a nomogram for predicting disease-specific survival after an R0 resection for gastric carcinoma..  103. 2005
• Do cancer centers designated by the National Cancer Institute have better surgical outcomes?.  103. 2005
• Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system..  103. 2005
• Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series..  103. 2005
• Multiple primary soft tissue sarcomas..  101. 2004
• Measuring circulating neuroblastoma cells by quantitative reverse transcriptase-polymerase chain reaction analysis..  101. 2004
• Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480..  101. 2004
• Validation of the postoperative nomogram for 12-year sarcoma-specific mortality..  101. 2004
• Feasibility and utility of using chromosomal aneusomy to further define the cytologic categories in nipple aspirate fluid specimens: a preliminary study..  102. 2004
• Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment..  101. 2004
• Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy..  101. 2004
• Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma..  101. 2004
• Cytokeratin-positive cells in sentinel lymph nodes in breast cancer are not random events: experience in patients undergoing prophylactic mastectomy..  101. 2004
• Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma..  101. 2004
• The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma..  101. 2004
• The utility of p16INK4a and Ki-67 staining on cell blocks prepared from residual thin-layer cervicovaginal material..  102. 2004
• Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma..  100. 2004
• The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy..  100. 2004
• Pathologic evaluation of radical cystectomy specimens: a cooperative group report..  100. 2004
• The development of interval breast malignancies in patients with BRCA mutations..  100. 2004
• Acceptance of tamoxifen chemoprevention by physicians and women at risk..  100. 2004
• High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma..  100. 2004
• Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma..  100. 2004
• Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial..  100. 2004
• Primary mucosal melanoma of the head and neck: a proposal for microstaging localized, Stage I (lymph node-negative) tumors..  100. 2004
• Survivin expression is associated with features of biologically aggressive prostate carcinoma..  100. 2004
• A clinically comprehensive ethical framework for offering and recommending cancer treatment before and during pregnancy..  100. 2004
• Is endometrial carcinoma intrinsically more aggressive in elderly patients?.  98. 2003
• Ductal lavage in patients undergoing mastectomy for mammary carcinoma: a correlative study..  98. 2003
• Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma..  98. 2003
• Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies..  98. 2003
• Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials..  98. 2003
• Craniofacial surgery for malignant skull base tumors: report of an international collaborative study..  98. 2003
• Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma..  98. 2003
• A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma..  98. 2003
• Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy..  98. 2003
• Comparison of ThinPrep and conventional smears in detecting carcinoma in bile duct brushings..  99. 2003
• Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy..  98. 2003
• Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma..  98. 2003
• Evidence of a preferred molecular pathway in patients with synchronous colorectal cancer..  98. 2003
• Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma..  98. 2003
• The memorial anxiety scale for prostate cancer: validation of a new scale to measure anxiety in men with with prostate cancer..  97. 2003
• Thyroid neoplasms after therapeutic radiation for malignancies during childhood or adolescence..  97. 2003
• Conservative management of Paget disease of the breast with radiotherapy: 10- and 15-year results..  97. 2003
• Nipple aspirate fluid cytology in breast carcinoma..  99. 2003
• Can patient selection for bladder preservation be based on response to chemotherapy?.  97. 2003
• Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations..  97. 2003
• Risk of lung carcinoma among users of nonsteroidal antiinflammatory drugs..  97. 2003
• Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias..  97. 2003
• Overdiagnosis in chest radiographic screening for lung carcinoma: frequency..  97. 2003
• The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions..  99. 2003
• Compliance with breast-conservation standards for patients with early-stage breast carcinoma..  97. 2003
• Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin..  97. 2003
• Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study..  97. 2003
• Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor..  97. 2003
• Long-term results of three-dimensional conformal radiation therapy for patients with rhabdomyosarcoma..  97. 2003
• Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma..  95. 2002
• Pathologic review of the Mayo Lung Project cancers [corrected]. Is there a case for misdiagnosis or overdiagnosis of lung carcinoma in the screened group?.  95. 2002
• Pulmonary complications in survivors of childhood and adolescent cancer. A report from the Childhood Cancer Survivor Study..  95. 2002
• An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up..  95. 2002
• Hepatic intraductal oncocytic papillary carcinoma..  95. 2002
• Conventional hemangiopericytoma: modern analysis of outcome..  95. 2002
• Second malignant neoplasms in long-term survivors of osteosarcoma: Memorial Sloan-Kettering Cancer Center Experience..  95. 2002
• Improved outcomes in patients with osteogenic sarcoma of the head and neck..  95. 2002
• Strategies for improving melanoma education and screening for men age >or= 50 years: findings from the American Academy of Dermatological National Skin Cancer Sreening Program..  95. 2002
• Chronic neuroblastoma..  95. 2002
• Factors that influence surgical choices in women with breast carcinoma..  95. 2002
• Phase I trial of interferon alpha2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma..  95. 2002
• Financial analysis of patients with newly diagnosed acute myelogenous leukemia on protocol or standard therapy..  95. 2002
• A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia..  95. 2002
• Pathologic evaluation of radical cystectomy specimens..  95. 2002
• The clinical course of nonsmall cell lung carcinoma in survivors of Hodgkin disease..  95. 2002
• High-grade gliomas in patients with prior systemic malignancies..  94. 2002
• Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8..  94. 2002
• Evolving significance of prognostic markers associated with treatment improvement in patients with stage 4 neuroblastoma..  94. 2002
• Soft tissue sarcoma brain metastases. Prevalence in a cohort of 3829 patients..  94. 2002
• Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma..  94. 2002
• Classification of benign endometrial glandular cells in cervical smears from postmenopausal women..  96. 2002
• Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors..  94. 2002
• Diagnostic utility of the HepPar1 antibody to differentiate hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration samples..  96. 2002
• Abnormalities of chromosome bands 15q13-15 in childhood acute lymphoblastic leukemia..  94. 2002
• Clinicopathologic correlates of solitary fibrous tumors..  94. 2002
• Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma..  94. 2002
• HER-2 profiling and targeting in prostate carcinoma..  94. 2002
• Rationales, evidence, and design considerations for fractionated radioimmunotherapy..  94. 2002
• Results of the Lynn Sage Second-Opinion Program for local therapy in patients with breast carcinoma. Changes in management and determinants of where care is delivered..  94. 2002
• Intraductal papillary-mucinous neoplasms of the pancreas: an analysis of in situ and invasive carcinomas in 28 patients..  94. 2002
• Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy..  92. 2001
• Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma..  92. 2001
• Comparison of two total body irradiation fractionation regimens with respect to acute and late pulmonary toxicity..  92. 2001
• Paclitaxel in the multimodality treatment for inflammatory breast carcinoma..  92. 2001
• Predictive value of expression of transforming growth factor-beta(1) and its receptors in transitional cell carcinoma of the urinary bladder..  92. 2001
• Testicular sperm extraction combined with intracytoplasmic sperm injection in the treatment of men with persistent azoospermia postchemotherapy..  92. 2001
• GD2 synthase: a new molecular marker for detecting neuroblastoma..  92. 2001
• High Ki-67 proliferative index predicts disease specific survival in patients with high-risk soft tissue sarcomas..  92. 2001
• Early lung cancer action project: initial findings on repeat screenings..  92. 2001
• Diagnosis, pathology, staging, treatment, and outcome of epithelial ovarian neoplasia in patients age < 21 years..  91. 2001
• Should the cytologic diagnosis of "atypical squamous cells of undetermined significance" be qualified? An assessment including comparison between conventional and liquid-based technologies..  93. 2001
• Microsatellite instability and hMLH1/hMSH2 expression in Barrett esophagus-associated adenocarcinoma..  91. 2001
• Alternative medicine use worldwide: the International Union Against Cancer survey..  91. 2001
• A clinical scoring system predicts the yield of diagnostic laparoscopy in patients with potentially resectable hepatic colorectal metastases..  91. 2001
• Salvage treatment for local recurrence after breast-conserving surgery and radiation as initial treatment for mammographically detected ductal carcinoma in situ of the breast..  91. 2001
• G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting..  91. 2001
• Clinicopathologic analysis of patients with adult rhabdomyosarcoma..  91. 2001
• Genetic variation in the tumor necrosis factor-alpha promoter region and in the stress protein hsp70-2: susceptibility and prognostic implications in breast carcinoma..  91. 2001
• Localized non-Hodgkin lymphoma involving the thyroid gland..  91. 2001
• The Collection of Indirect and Nonmedical Direct Costs (COIN) form: a new tool for collecting the invisible costs of androgen independent prostate carcinoma..  91. 2001
• Reducing the cost of diagnosis of breast carcinoma: impact of ultrasound and imaging-guided biopsies on a clinical breast practice..  91. 2001
• Survival analysis of clinical, pathologic, and genetic features in neuroblastoma presenting as locoregional disease..  91. 2001
• A phase II study of irinotecan in patients with advanced hepatocellular carcinoma..  91. 2001
• Imaging-histologic discordance at percutaneous breast biopsy..  89. 2000
• Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma..  89. 2000
• In microdissected ductal carcinoma in situ, HER-2/neu amplification, but not p53 mutation, is associated with high nuclear grade and comedo histology..  89. 2000
• Is gastric carcinoma different between Japan and the United States?.  89. 2000
• Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma..  89. 2000
• Successful treatment of metastatic retinoblastoma..  89. 2000
• Prognostic impact of INK4A deletion in Ewing sarcoma..  89. 2000
• Prognostic impact of P53 status in Ewing sarcoma..  89. 2000
• Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes..  89. 2000
• Patterns of detection in patients with cutaneous melanoma..  89. 2000
• Telomerase activity in B-cell non-Hodgkin lymphoma..  89. 2000
• A comparison of staging systems for localized extremity soft tissue sarcoma..  88. 2000
• Dermatofibrosarcoma protuberans: A clinicopathologic analysis of patients treated and followed at a single institution..  88. 2000
• Identification and characterization of circulating prostate carcinoma cells..  88. 2000
• The schedule of attitudes toward hastened death: Measuring desire for death in terminally ill cancer patients..  88. 2000
• Prognostic significance of cytogenetic abnormalities of chromosome arm 12p in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group..  88. 2000
• Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules..  88. 2000
• Phase I trial of docetaxel and vinorelbine in patients with advanced nonsmall cell lung carcinoma..  88. 2000
• A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181..  88. 2000
• National Cancer Data Base survey of breast cancer management for patients from low income zip codes..  88. 2000
• Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues..  88. 2000
• Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection..  88. 2000
• Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladder..  86. 1999
• Extremity and trunk desmoid tumors: a multifactorial analysis of outcome..  86. 1999
• Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face..  86. 1999
• Long term follow-up of women with ductal carcinoma in situ treated with breast-conserving surgery: the effect of age..  86. 1999
• The clinical course of lung carcinoma in patients with chronic lymphocytic leukemia..  86. 1999
• Induction chemotherapy employing dose-intense cisplatin with mitomycin and vinblastine (MVP400), followed by thoracic surgery or irradiation, for patients with stage III nonsmall cell lung carcinoma..  86. 1999
• Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma..  86. 1999
• Localized male breast carcinoma and family history. An analysis of 142 patients..  86. 1999
• Cytopathology of insular carcinoma of the thyroid..  87. 1999
• The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase-polymerase chain reaction assay for MN/CA9..  86. 1999
• Evaluation of chest computed tomography in the staging of patients with potentially resectable liver metastases from colorectal carcinoma..  86. 1999
• The cytology of extraskeletal Ewing sarcoma..  87. 1999
• B-lineage lymphoblastic lymphoma is a clinicopathologic entity distinct from other histologically similar aggressive lymphomas with blastic morphology..  85. 1999
• Malignant fibrous histiocytoma of the extremity..  85. 1999
• Phase II clinical trial of 13-cis-retinoic acid and interferon-alpha-2a in patients with advanced esophageal carcinoma..  85. 1999
• Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma..  85. 1999
• Childhood melanoma survival..  85. 1999
• Genetic changes in the spectrum of neuroendocrine lung tumors..  85. 1999
• Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma..  85. 1999
• Predictors of local recurrence following excision alone for ductal carcinoma in situ..  85. 1999
• Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck..  85. 1999
• Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas..  83. 1998
• Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies: a report from the Children's Cancer Group..  83. 1998
• Malignant vascular tumors in young patients..  83. 1998
• Skeletal and extraskeletal myxoid chondrosarcoma: a comparative clinicopathologic, ultrastructural, and molecular study..  83. 1998
• Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin..  83. 1998
• The National Cancer Data Base 10-year survey of breast carcinoma treatment at hospitals in the United States..  83. 1998
• Gallbladder carcinoma discovered during laparoscopic cholecystectomy: aggressive reresection is beneficial..  83. 1998
• Ki-67 detected by MIB-1 predicts distant metastasis and tumor mortality in primary, high grade extremity soft tissue sarcoma..  83. 1998
• Pathologic femoral fracture after periosteal excision and radiation for the treatment of soft tissue sarcoma..  82. 1998
• Subdiaphragmatic and intrathoracic paraspinal malignant peripheral nerve sheath tumors: a clinicopathologic study of 25 patients and 26 tumors..  82. 1998
• Preoperative galactography increases the diagnostic yield of major duct excision for nipple discharge..  82. 1998
• Rapid screening for psychologic distress in men with prostate carcinoma: a pilot study..  82. 1998
• The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevant..  82. 1998
• Prognostic factors for patients with sarcomas of the pelvic bones..  82. 1998
• Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity..  82. 1998
• Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group..  82. 1998
• The role of surgery in the treatment of clinically isolated adrenal metastasis..  82. 1998
• Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery..  82. 1998
• Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding..  80. 1997
• Single chain antigen binding protein (sFv CC49): first human studies in colorectal carcinoma metastatic to liver..  80. 1997
• Long-term follow-up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with untreated acute myeloid leukemia..  80. 1997
• 9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma..  80. 1997
• Results of hospital cancer registry surveys by the American College of Surgeons: outcomes of prostate cancer treatment by radical prostatectomy..  80. 1997
• Surgical treatment of 70 patients with brain metastases from breast carcinoma..  80. 1997
• Chest wall rhabdomyosarcoma..  80. 1997
• Polymorphism in the tumor necrosis factor-alpha promotor region and in the heat shock protein 70 genes associated with malignant tumors..  80. 1997
• Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells..  80. 1997
• Thallium-201 scintigraphy for the evaluation of tumor response to preoperative chemotherapy in patients with osteosarcoma..  80. 1997
• The conservative management of Paget's disease of the breast with radiotherapy..  80. 1997
• The role of dietary factors in the intestinal and diffuse histologic subtypes of gastric adenocarcinoma: a case-control study in the U.S..  80. 1997
• Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors..  80. 1997
• Kaposi's sarcoma-associated herpesvirus sequences in benign lymphoid proliferations not associated with human immunodeficiency virus..  80. 1997
• Thyroid dysfunction as a late effect in survivors of pediatric medulloblastoma/primitive neuroectodermal tumors: a comparison of hyperfractionated versus conventional radiotherapy..  80. 1997
• Psychologic aspects of cancer genetic testing: a research update for clinicians..  80. 1997
• The American Society of Clinical Oncology position on genetic testing: implications for health care providers: workshop no. 4..  80. 1997
• Influence of nativity on cancer mortality among black New Yorkers..  80. 1997
• Fine-needle aspiration biopsy in the diagnosis and management of bone lesions: a study of 450 cases..  81. 1997
• Solitary fibrous tumor. A cytologic-histologic study with clinical, radiologic, and immunohistochemical correlations..  81. 1997
• All-trans retinoic acid and interferon-alpha-2a in patients with metastatic or recurrent carcinoma of the uterine cervix: clinical and pharmacokinetic studies. New York Gynecologic Oncology Group..  79. 1997
• p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate..  79. 1997
• Patterns of mammographically detected calcifications after breast-conserving therapy associated with tumor recurrence..  79. 1997
• Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a,bNOMO): clinicopathologic features and outcome..  79. 1997
• Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma..  79. 1997
• Small cell neuroendocrine carcinoma of the urinary bladder. A clinicopathologic study with emphasis on cytologic features..  79. 1997
• A national survey of attitudes regarding participation in prostate carcinoma testing..  78. 1996
• A phase I trial of a modified, dose intensive FAMTX regimen (high dose 5-fluorouracil+doxorubicin+high dose methotrexate+leucovorin) with oral uridine rescue..  78. 1996
• Clinical presentations and RET protooncogene mutations in seven multiple endocrine neoplasia type 2 kindreds..  78. 1996
• Graft-versus-host disease. Possible higher risk for African American patients..  78. 1996
• The National Cancer Data Base report on bladder carcinoma. The American College of Surgeons Commission on Cancer and the American Cancer Society..  78. 1996
• Perineural invasion of prostate carcinoma cells is associated with reduced apoptotic index..  78. 1996
• Transitions in the care of adolescent and young adult survivors of childhood cancer..  78. 1996
• Comparison of DNA topoisomerase II alpha expression in small cell and nonsmall cell carcinoma of the lung. In search of a mechanism of chemotherapeutic response..  78. 1996
• Treatment of femoral Ewing's sarcoma..  78. 1996
• United States lung carcinoma incidence trends: declining for most histologic types among males, increasing among females..  77. 1996
• Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma..  77. 1996
• Post-irradiation malignant mesothelioma..  77. 1996
• The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis..  77. 1996
• Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome..  77. 1996
• Second malignant neoplasms in long-term survivors of childhood rhabdomyosarcoma..  76. 1995
• The National Cancer Data Base report on pancreatic cancer..  76. 1995
• p53 protein accumulation in tumors of the ampulla of Vater..  76. 1995
• Characteristics of follicular tumors and nonneoplastic thyroid lesions in children and adolescents exposed to radiation as a result of the Chernobyl disaster..  76. 1995
• Oral combination antiemetics in patients with small cell lung cancer receiving cisplatin or cyclophosphamide plus doxorubicin..  76. 1995
• Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma..  76. 1995
• all-trans retinoic acid for treating germ cell tumors. In vitro activity and results of a phase II trial..  76. 1995
• Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel..  76. 1995
• A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma..  75. 1995
• A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma..  75. 1995
• A phase II trial of extracorporeal plasma immunoadsorption of patient plasma with PROSORBA columns for treating metastatic breast cancer..  75. 1995
• Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis..  75. 1995
• Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer..  75. 1995
• A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer..  75. 1995
• Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer..  75. 1995
• Prevalence and predictors of continued tobacco use after treatment of patients with head and neck cancer..  75. 1995
• The frequency of apoptosis correlates with the prognosis of Gleason Grade 3 adenocarcinoma of the prostate..  75. 1995
• Lung cancer..  75. 1995
• Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer..  75. 1995
• Relationship of P-glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion, DNA ploidy, and disease relapse..  74. 1994
• A phase I trial of intrahepatic verapamil and doxorubicin. Regional therapy to overcome multidrug resistance..  74. 1994
• A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer..  74. 1994
• In vitro modulation of the invasive and metastatic potentials of human renal cell carcinoma by interleukin-2 and/or interferon-alpha gene transfer..  74. 1994
• Conservative surgery for giant cell tumors of the sacrum. The role of cryosurgery as a supplement to curettage and partial excision..  74. 1994
• Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors..  74. 1994
• The management of high grade dysplasia and early cancer in Barrett's esophagus. A multidisciplinary problem..  74. 1994
• A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors..  74. 1994
• Immunohistochemical detection of bone morphogenetic proteins in bone and soft-tissue sarcomas..  74. 1994
• Prognostic factors for recurrence and survival in head and neck soft tissue sarcomas..  74. 1994
• The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations..  74. 1994
• Long term results of stereotactic brachytherapy used in the initial treatment of patients with glioblastomas..  73. 1994
• Pleomorphic (spindle/giant cell) carcinoma of the lung. A clinicopathologic correlation of 78 cases..  73. 1994
• The role of pelvic lymphadenectomy and radical cystectomy for lymph node positive bladder cancer. The Memorial Sloan-Kettering Cancer Center experience..  73. 1994
• Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay..  73. 1994
• Quality of life of patients with prostate cancer and their spouses. The value of a data base in clinical care..  73. 1994
• Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy..  73. 1994
• Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale..  73. 1994
• Preoperative and postoperative adjuvant combination chemotherapy for adults with high grade soft tissue sarcoma..  73. 1994
• Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia..  73. 1994
• Radiobiologic studies of low-dose-rate 90Y-lymphoma therapy..  73. 1994
• The addition of ondansetron to the combination of metoclopramide, dexamethasone, and lorazepam did not improve vomiting prevention in patients receiving high-dose cisplatin..  73. 1994
• Preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for rectal cancer..  73. 1994
• Therapy of venous thromboembolism in patients with brain metastases..  73. 1994
• Defining the invasive phenotype of proximal gastric cancer cells..  73. 1994
• Partial nephrectomy for renal cell carcinoma with a normal opposite kidney..  73. 1994
• Phase II trial of gemcitabine in patients with advanced gastric cancer..  73. 1994
• The effect of age at diagnosis on outcome in rhabdomyosarcoma..  73. 1994
• Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial..  72. 1993
• CD30 (Ki-1) positive anaplastic large cell lymphomas in individuals infected with the human immunodeficiency virus..  72. 1993
• Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol..  72. 1993
• Expression and modulation of class I and class II histocompatibility leukocyte antigens on human soft tissue sarcomas..  72. 1993
• Liposarcoma in patients younger than or equal to 22 years of age..  72. 1993
• Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis..  72. 1993
• Dose-ranging antiemetic evaluation of the serotonin antagonist RG 12915 in patients receiving anticancer chemotherapy..  72. 1993
• Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for infiltrating transitional cell carcinoma of the bladder..  72. 1993
• Characterization of cell lines established from human gastric-esophageal adenocarcinomas. Biologic phenotype and invasion potential..  72. 1993
• Edatrexate in patients with soft tissue sarcoma. Activity in malignant fibrous histiocytoma..  72. 1993
• The clinical spectrum of ocular lymphoma..  72. 1993
• A phase II trial of carboplatin in patients with advanced APUD tumors..  72. 1993
• Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors..  72. 1993
• Prognosis of operable squamous cell carcinoma of the esophagus. Relationship with clinicopathologic features and DNA ploidy..  72. 1993
• Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma..  71. 1993
• The efficacy of preoperative 5-fluorouracil, high-dose leucovorin, and sequential radiation therapy for unresectable rectal cancer..  71. 1993
• Young adults 16-21 years of age at diagnosis entered on Childrens Cancer Group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols. Results of treatment..  71. 1993
• Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor. A randomized trial..  71. 1993
• Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast-conserving surgery and definitive irradiation. Correlation of pathologic parameters with outcome of treatment..  71. 1993
• Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study..  71. 1993
• A pilot study of hepatic artery floxuridine combined with systemic 5-fluorouracil and leucovorin. A potential adjuvant program after resection of colorectal hepatic metastases..  71. 1993
• Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin..  71. 1993
• Phase II trial of carboplatin and etoposide in metastatic breast cancer..  71. 1993
• A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy..  71. 1993
• Epithelial ovarian cancer in the elderly. The Memorial Sloan-Kettering Cancer Center experience..  71. 1993
• Dose-ranging antiemetic evaluation of the serotonin antagonist tropisetron in patients receiving anti-cancer chemotherapy..  71. 1993
• Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy..  70. 1992
• Spinal epidural tumor in patients with prostate cancer. Clinical and radiographic predictors of response to radiation therapy..  70. 1992
• Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers..  70. 1992
• A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site..  70. 1992
• Epstein-Barr virus in acquired immune deficiency syndrome (AIDS) and non-AIDS primary central nervous system lymphoma..  70. 1992
• Pain in ambulatory patients with lung or colon cancer. Prevalence, characteristics, and effect..  70. 1992
• Prognostic significance of DNA quantitation in stage D1 prostate carcinoma with the use of image analysis..  70. 1992
• The National Polyp Study. Design, methods, and characteristics of patients with newly diagnosed polyps. The National Polyp Study Workgroup..  70. 1992
• Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas..  70. 1992
• Detection of local recurrence after conservative therapy for breast carcinoma..  70. 1992
• Pseudomyxoma peritonei of appendiceal origin. The Memorial Sloan-Kettering Cancer Center experience..  70. 1992
• Tendosynovial sarcoma. Clinicopathologic features, treatment, and prognosis..  70. 1992
• Is screening for breast cancer cost-effective?.  69. 1992
• Legal aspects, legislative effect, cost effectiveness, and barriers to breast cancer screening..  69. 1992
• Four cycles of chemotherapy and regional radiation therapy for clinical early-stage and intermediate-stage Hodgkin's disease..  69. 1992
• Treatment of unresectable primary liver cancer with intrahepatic fluorodeoxyuridine and mitomycin C through an implantable pump..  69. 1992
• Correlation between side of palpable tumor and side of pelvic lymph node metastasis in clinically localized prostate cancer..  69. 1992
• A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer..  69. 1992
• High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated..  69. 1992
• A flow cytometric study of non-small cell lung cancer classified as T1N0..  69. 1992
• Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors..  68. 1991
• Ten-year results of breast-conserving surgery and definitive irradiation for intraductal carcinoma (ductal carcinoma in situ) of the breast..  68. 1991
• An ultrastructural study of in vivo interactions between lymphocytes and endothelial cells in the pathogenesis of the vascular leak syndrome induced by interleukin-2..  68. 1991
• Transurethral resection of the prostate and metastatic prostate cancer..  68. 1991
• Cytosine arabinoside and cisplatin for advanced breast cancer. A phase II study of the Cancer and Leukemia Group B..  68. 1991
• Localization of endocrine tumors of the pancreas with endoscopic ultrasonography..  68. 1991
• A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma..  68. 1991
• A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors..  68. 1991
• Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia..  68. 1991
• A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma..  68. 1991
• Lymphomatous presentation of childhood acute lymphoblastic leukemia. A subgroup at high risk of early treatment failure..  68. 1991
• High-dose melphalan with 6-hydroxydopamine-purged autologous bone marrow transplantation for poor-risk neuroblastoma..  68. 1991
• Preoperative high-dose leucovorin/5-fluorouracil and radiation therapy for unresectable rectal cancer..  67. 1991
• Retinoblastoma. The long-term appearance of radiated intraocular tumors..  67. 1991
• Evolution of neuropathy and myopathy during intensive vincristine/corticosteroid chemotherapy for non-Hodgkin's lymphoma..  67. 1991
• Extragonadal and poor risk nonseminomatous germ cell tumors. Survival and prognostic features..  67. 1991
• Extracranial primitive neuroectodermal tumors. The Memorial Sloan-Kettering Cancer Center experience..  67. 1991
• Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy..  67. 1991
• Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989)..  67. 1991
• Serum tumor markers and patient allocation to good-risk and poor-risk clinical trials in patients with germ cell tumors..  67. 1991
• A phase II trial of carboplatin and vinblastine in the treatment of advanced squamous cell carcinoma of the esophagus..  67. 1991
• Combined surgical resection and iridium 192 implantation for locally advanced and recurrent desmoid tumors..  67. 1991
• Insulin secretion and action in patients with pancreatic cancer..  67. 1991
• Two-drug therapy in patients with metastatic germ cell tumors..  67. 1991
• Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Assessment of activity and toxicity..  66. 1990
• The role of autologous tumor cells in preventing lymphokine-activated killer cell induction in vitro..  66. 1990
• The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors..  66. 1990
• A randomized comparison of methotrexate dose and the addition of bleomycin to CHOP therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas. Cancer and Leukemia Group B study 7851..  66. 1990
• A phase I trial of cisplatin in hypertonic saline and escalating doses of 5-fluorouracil by continuous intravenous infusion in patients with advanced malignancies..  66. 1990
• Comparison of the conventional method of lymph node staging with a comprehensive fat-clearing method for gastric adenocarcinoma..  66. 1990
• Myocarditis or acute myocardial infarction associated with interleukin-2 therapy for cancer..  66. 1990
• Cellular schwannoma. A clinicopathologic study of 57 patients and 58 tumors..  66. 1990
• Dose-intensive use of cyclophosphamide in ablation of neuroblastoma..  66. 1990
• Radiation therapy after breast augmentation or reconstruction in early or recurrent breast cancer..  66. 1990
• The effect of a 7-day delay in chemotherapy cycles on complete response and event-free survival in good-risk disseminated germ cell tumor patients..  66. 1990
• A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinoma..  66. 1990
• Delayed central nervous system (CNS) radiation in childhood CNS acute lymphoblastic leukemia. Results of a pilot trial..  66. 1990
• Targeted cytogenetic analysis of gastric tumors by in situ hybridization with a set of chromosome-specific DNA probes..  66. 1990
• Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumors..  65. 1990
• Continuous intrahepatic infusion of floxuridine and leucovorin through an implantable pump for the treatment of hepatic metastases from colorectal carcinoma..  65. 1990
• DNA content of rectal scrapings from individuals at low and high risk for the development of colorectal cancer. A feasibility study..  64. 1989
• Diaziquone and 2,2'-anhydro-arabinosyl-5-fluorocytosine for the treatment of children with relapsed or refractory acute nonlymphoblastic leukemia..  64. 1989
• Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse..  64. 1989
• Intrahepatic mitomycin C as a salvage treatment for patients with hepatic metastases from colorectal carcinoma..  64. 1989
• Small cell carcinoma of the esophagus. The Memorial Hospital experience 1970 to 1987..  64. 1989
• The prognostic value of histologic subtypes in primary extremity liposarcoma..  64. 1989
• Individual risk of abdominal disease in patients with stages I and II supradiaphragmatic Hodgkin's disease. A rule index based on 341 laparotomized patients..  63. 1989
• Reinduction therapy for advanced or refractory acute lymphoblastic leukemia of childhood..  63. 1989
• Cisplatin and 5-fluorouracil infusion for metastatic colorectal carcinoma. Differences in survival in two patient groups with similar response rates..  63. 1989
• Interstitial brachytherapy for metastatic brain tumors..  63. 1989
• Prognostic factors for relapse after complete response in patients with metastatic germ cell tumors..  63. 1989
• Alveolar soft-part sarcoma. A clinico-pathologic study of half a century..  63. 1989
• Flow cytometric analysis of pituitary tumors. Correlation of nuclear antigen p105 and DNA content with clinical behavior..  62. 1988
• Significance of systemic mast cell disease with associated hematologic disorders..  62. 1988
• Low-grade soft tissue sarcomas of the extremities. Analysis of risk factors for metastasis..  62. 1988
• Long-term survival after resection of ampullary carcinoma is associated independently with tumor grade and a new staging classification that assesses local invasiveness..  61. 1988
• Patient compliance with aggressive multimodal therapy in locally advanced breast cancer..  61. 1988
• Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial..  60. 1987
• Distinguishing features of primary hyperparathyroidism in patients with breast cancer..  60. 1987
• The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma..  60. 1987
• Quality of life measurement in testicular cancer patients..  60. 1987
• The Memorial Pain Assessment Card. A valid instrument for the evaluation of cancer pain..  60. 1987
• The practical use of tumor marker determination in bladder washing specimens. Assessing the urothelium of patients with superficial bladder cancer..  60. 1987
• Malignant lymphomas in a population at risk for acquired immune deficiency syndrome..  60. 1987
• Abnormal colony formation and prostaglandin E responsiveness of myeloid progenitor cells in patients cured of germ cell neoplasms after combination chemotherapy..  60. 1987
• Monoclonal antibodies in urologic oncology..  60. 1987
• Strategies for the management of recurrent and advanced urologic cancers. Quality of life..  60. 1987
• Toxicity of intravesical BCG and its management in patients with superficial bladder tumors..  60. 1987
• Urologic cancer. Methods of early detection and future developments..  60. 1987
• Testicular failure in patients with extragonadal germ cell tumors..  60. 1987
• The sensitivity of flow cytometry compared with conventional cytology in the detection of superficial bladder carcinoma..  59. 1987
• Acute chest pain syndrome during bleomycin infusions..  59. 1987
• Smoking, body weight, and early-stage endometrial cancer..  59. 1987
• Lactase dehydrogenase as a tumor marker for recurrent disease in Ewing's sarcoma..  59. 1987
• Intermittent endocrine therapy for advanced prostate cancer..  58. 1986
• A pilot study of cisplatin-vinblastine as the initial treatment of advanced head and neck cancer..  58. 1986
• Clinical study of a new antimetastatic compound, Nafazatrom (Bay g 6575). Effects on platelet consumption and monocyte prostaglandin production in patients with advanced cancer..  57. 1986
• Kaposi's sarcoma and the acquired immune deficiency syndrome. Treatment with recombinant interferon alpha and analysis of prognostic factors..  57. 1986
• Limb preservation and tumor control in the treatment of popliteal and antecubital soft tissue sarcomas..  57. 1986
• Sequential excision of residual thoracic and retroperitoneal masses after chemotherapy for stage III germ cell tumors..  57. 1986
• Transrectal ultrasonography for prostatic cancer. II. The response of the prostate to definitive radiotherapy..  57. 1986
• Intraluminal radiation therapy in the management of malignant biliary obstruction..  57. 1986
• Increased survival with high-dose multifield radiotherapy and intensive chemotherapy in limited small cell carcinoma of the lung..  56. 1985
• Adenocarcinoma of the esophagus and gastroesophageal junction. Prognostic factors and results of therapy..  56. 1985
• Metastatic neuroblastoma and testicular involvement..  56. 1985
• Fasting plasma amino acid levels in cancer patients..  56. 1985
• Preoperative intra-arterial infusion chemotherapy for advanced squamous cell carcinoma of the mouth and oropharynx..  56. 1985
• Retroperitoneal germ cell tumors in childhood. A clinical and pathologic study of 11 cases..  56. 1985
• HAC-Cytoxan (cyclophosphamide) chemotherapy for ovarian carcinoma. Alternating chemotherapy with intensification..  55. 1985
• Terminal deoxynucleotidyl transferase activity in childhood leukemia..  55. 1985
• A randomized, prospective trial of adjuvant chemotherapy in adults with soft tissue sarcomas of the head and neck, breast, and trunk..  55. 1985
• Correlation of erythrocyte and plasma levels of zinc, copper, and iron with evidence of metastatic spread in cancer patients..  55. 1985
• Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients..  55. 1985
• Glucose intolerance in sarcoma patients..  54. 1984
• Cisplatin and bleomycin in the treatment of esophageal carcinoma. A final report..  54. 1984
• Metabolic consequences of nutritional support of the cancer patient..  54. 1984
• Monoclonal antibodies to breast cancer-associated antigens as potential reagents in the management of breast cancer..  54. 1984
• New therapeutic approaches for brain tumors..  54. 1984
• T-lymphocyte subpopulations in B-cell-derived non-Hodgkin's lymphomas and Hodgkin's disease..  54. 1984
• Estrogen, progesterone, and androgen-binding sites in renal cell carcinoma. Observations obtained in Phase II trial of flutamide..  54. 1984
• Intracranial metastases in prostate cancer..  53. 1984
• Testicular function following bone marrow transplantation performed during or after puberty..  53. 1984
• Comparison of antigen expression of human renal cancers in vivo and in vitro..  53. 1984
• Does clearing of axillary lymph nodes contribute to accurate staging of breast carcinoma?.  53. 1984
• Intraarterial versus intravenous adriamycin in the rabbit Vx-2 tumor system..  53. 1984
• Potentiation of methylglyoxal-bis-guanylhydrazone by alpha-difluoromethylornithine in rat prostate cancer..  53. 1984
• Vertebral body resection in the treatment of cancer involving the spine..  53. 1984
• Whole-body protein metabolism in cancer-bearing patients. Effect of total parenteral nutrition and associated serum insulin response..  53. 1984
• Adult non-Hodgkin's lymphoma. Correlation of cell surface marker phenotype with prognosis, the new working formulation, and the Rappaport and Lukes-Collins histomorphologic schemes..  52. 1983
• Planned preoperative cisplatin and radiation therapy for locally advanced bladder cancer..  52. 1983
• Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group..  52. 1983
• Cooperative groups and community hospitals. Measurement of impact in the community hospitals..  52. 1983
• Prospective randomized evaluation of adjuvant chemotherapy in adults with soft tissue sarcomas of the extremities..  52. 1983
• Interrelationships of histopathology and other clinical variables in patients with germ cell tumors of the testis..  51. 1983
• Severe pneumococcal infection in patients with neoplastic disease..  51. 1983
• Effect of intravesical Bacillus Calmette-Guerin (BCG) on carcinoma in situ of the bladder..  51. 1983
• Inferior pubic rami resection with en bloc radical excision for invasive proximal urethral carcinoma..  51. 1983
• Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone..  51. 1983
• Cisplatin, vindesine and bleomycin (CVB) combination chemotherapy of advanced non-small cell lung cancer..  51. 1983
• Association of depressed mixed lymphocyte reactivity with the development of bladder carcinoma in patients with papillomas..  51. 1983
• Metastatic colorectal carcinoma. A prospective randomized trial of Methyl-CCNU, 5-Fluorouracil (5-FU) and vincristine (MOF) versus MOF plus streptozotocin (MOF-Strep)..  51. 1983
• VAB-6 combination chemotherapy in resected stage II-B testis cancer..  51. 1983
• Treatment of advanced esophageal cancer..  50. 1982
• Continuous infusion vincristine and bleomycin with high dose methotrexate for resistant non-Hodgkin's lymphoma..  50. 1982
• Characterization of two newly established human cell lines from patients with large-cell anaplastic lung carcinoma..  50. 1982
• Tumor classification and size in germ-cell testicular cancer: influence on the occurrence of metastases..  50. 1982
• Role of chemotherapy and surgery in the treatment of thoracic metastases from nonseminomatous germ cell testis tumor..  50. 1982
• Soft tissue sarcomas of the extremities: survival and patterns of failure with conservative surgery and postoperative irradiation compared to surgery alone..  50. 1982
• An evaluation of automated flow cytometry (FCM) in detection of carcinoma in situ of the urinary bladder..  50. 1982
• Detection and follow-up of carcinoma of the urinary bladder by flow cytometry..  50. 1982
• The immunologic characterization of 40 extranodal lymphoid infiltrates: usefulness in distinguishing between benign pseudolymphoma and malignant lymphoma..  49. 1982
• A controlled, prospective, randomized trial evaluating the metabolic effects of enteral and parenteral nutrition in the cancer patient..  49. 1982
• Combination chemotherapy of esophageal carcinoma using cisplatin, vindesine, and bleomycin..  49. 1982
• Resting and activity energy expenditure during total parenteral nutrition in rats with methylcholanthrene-induced sarcoma..  49. 1982
• The impact of total parenteral nutrition on liver function tests in patients with cancer..  49. 1982
• Correlation of histochemical and biochemical analyses of androgen binding in prostatic cancer: relation to therapeutic response..  49. 1982
• Preoperative irradiation and cystectomy for bladder cancer..  49. 1982
• Immunoregulation by blasts from null cell and T-cell leukemias: help and suppression of T-cell proliferative responses to mitogens..  49. 1982
• Comparison of the response to PHA and suppressor macrophage function in different age groups of cancer patients and healthy controls..  48. 1981
• Randomized trial of standard therapy with or without poly I:C in patients with superficial bladder cancer..  48. 1981
• Small cell lung cancer: analysis of treatment factors contributing to prolonged survival..  48. 1981
• Multivariate analysis of T-cell functional defects and circulating serum factors in Hodgkin's disease..  48. 1981
• Combined modality therapy of esophageal carcinoma..  48. 1981
• Combined chemotherapy and surgery in treatment of advanced germ-cell tumors..  47. 1981
• Metabolic alterations in a noncachectic animal tumor system..  47. 1981
• Tumor markers in advanced nonseminomatous testicular cancer..  47. 1981
• Human chorionic gonadotropin and alphafetoprotein in the staging of nonseminomatous testicular cancer..  47. 1981
• Clinicopathologic relationships, survival, and therapy in 59 patients with observations on occupation as a new prognostic factor..  46. 1980
• Immunotherapy with oral BCG and serial immune evaluation in childhood lymphoblastic leukemia following three years of chemotherapy..  46. 1980
• Serum zinc, copper, and the Cu/Zn ratio in patients with benign and malignant breast lesions..  46. 1980
• Pharmacokinetics of gallium nitrate in man..  46. 1980
• Extracardiac rhabdomyoma: a clinicopathologic study and review of the literature..  46. 1980
• Intensive five-drug combination chemotherapy for adult acute non-lymphocytic leukemia..  46. 1980
• Orbital lymphoid neoplasms: a clinicopathologic study of 60 patients..  46. 1980
• Prognostic significance of serum lactate dehydrogenase in malignant lymphoma..  46. 1980
• In vivo utilization of substrate by human sarcoma-bearing limbs..  45. 1980
• A study of adriamycin-reduced wound breaking strenght in rats. An evaluation by light and electron microscopy, induction of collagen maturation, and hydroxyproline content..  45. 1980
• Time dependent effects of adriamycin and x-ray therapy on wound healing in the rat..  45. 1980
• Combination clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacologic evaluation..  45. 1980
• Influenza immunization of children with neoplastic diseases..  45. 1980
• Peripheral neuropathy associated with cis-dichlorodiammineplatinum (II) treatment..  44. 1979
• Acute non-lymphocytic leukemia and acute myeloproliferative syndrome following radiation therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia: cytogenetic studies..  44. 1979
• Acute nonlymphocytic leukemia and acute myeloproliferative syndrome following radiation therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia: clinical studies..  44. 1979
• A comparison between combination chemotherapy and total body irradiation plus combination chemotherapy in non-Hodgkin's lymphoma..  43. 1979
• The quantitative and qualitative impairment of wound healing by adriamycin..  43. 1979
• Anticoagulation and high dose liver radiation: a preliminary report..  43. 1979
• The influence of chemotherapy on response of patients with hematologic malignancies to influenza vaccine..  43. 1979
• Cardiac candidiasis in cancer patients..  41. 1978
• Results of combined chemo-surgical therapy for pulmonary metastases from testicular carcinoma..  41. 1978
• Immunologic reactivity in patients with primary operable breast cancer..  41. 1978
• High dose methotrexate with citrovorum factor in adult resistant lymphoma..  40. 1977
• The treatment of mycosis fungoides: adjuvant topical mechlorethamine after electron beam therapy..  40. 1977
• Cellular localization of alpha-fetoprotein and human chorionic gonadotropin in germ cell tumors of the testis using and indirect immunoperoxidase technique..  40. 1977
• The long term effects of radiation of T and B lymphocytes in the peripheral blood after regional irradiation..  40. 1977
• Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up..  40. 1977
• The coexistence of nodular and diffuse patterns in nodular non-Hodgkin's lymphomas: significance and clinicopathologic correlation..  40. 1977
• Radiotherapy results for nodular sclerosing Hodgkin's disease after clinical staging..  39. 1977
• A comparative study of some pathologic features of mammary carcinoma in Tokyo, Japan and New York, USA..  39. 1977
• Intrathecal N, N', N"-triethylenethiophosphoramide [thio-TEPA (NSC 6396)] in the treatment of malignant meningeal disease: phase I-II study..  38. 1976
• Proximal tubular adenomas of kidney with so-called oncocytic features. A clinicopathologic study of 13 cases of a rarely reported neoplasm..  38. 1976
• Abdominal irradiation in non-Hodgkin's lymphomas..  37. 1976
• Non-Hodgkin's lymphomas of stage III extent. Is total lymphoid irradiation appropriate treatment?.  37. 1976
• Quantitation of T and B lymphocytes and cellular immune function in Hodgkin's disease..  36. 1975
• Explorotory study of proton radiation therapy using large field techniques and fractionated dose schedules..  35. 1975
• Phase II study of procarbazine, CCNU, and vincristine combination chemotherapy in the treatment of malignant brain tumors..  35. 1975
• Indications for pleurectomy in malignant effusion..  35. 1975
• Of birds and mice and men: comments on the use of animal models and molecular hybridization in the search for human tumor viruses..  34. 1974
• Lymphography in mycosis fungoides..  34. 1974
• The role of lymphography in patients with ovarian cancer..  34. 1974
• Prognostic signs and the management of the mycosis fungoides..  32. 1973
• Non-Hodgkin's lymphomas. V. Results of radiotherapy..  32. 1973
• Staging laparotomies in unselected previously untreated patients with non-Hodgkin's lymphomas..  32. 1973
• Liver-spleen scan in Hodgkin's disease..  31. 1973
• Non-Hodgkin's lymphomas. IV. Clinicopathologic correlation in 405 cases..  31. 1973
• Extraskeletal spread in multiple plasma cell myeloma. A review of 57 autopsied cases..  23. 1969
• Two histologically different primary carcinomas of the lung. A review of the literature and presentation of a case..  22. 1968
• Reply to "Switching the scope from 'how to identify cancer survivors' to 'who is participating in cancer survivorship research': A proposal for a new focus"..  128. 2022
• Reply to The risk factors of upgrading in prostate cancer..  126. 2020
• Reply to Hope, optimism, and the importance of caregivers in end-of-life care..  125. 2019
• Reply to Effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer: Do we have certainties today?.  125. 2019
• Reply to Distinguishing between CISNET model results versus CISNET models..  124. 2017
• Reply to Opportunity cost of annual screening mammography..  124. 2017
• Reply to Urinary toxicity after stereotactic body radiotherapy: The boy who cried wolf?.  123. 2016
• Reply to "Twistin' the night away": Fertility preservation in young adult female cancer survivors..  123. 2016
• Reply to breast cancer risk by the extent and type of atypical hyperplasia..  122. 2016
• Reply to discrepant results for smoking and cessation among electronic cigarette users..  121. 2015
• Osteochondroma in long-term survivors of high-risk neuroblastoma..  121. 2015
• Reply to US lung cancer trends by histologic type..  121. 2014
• Patient-derived xenografts for individualized care in advanced sarcoma..  120. 2014
• Successful treatment of refractory metastatic histiocytic sarcoma with alemtuzumab..  118. 2011
• Gemcitabine-related radiation recall preferentially involves internal tissue and organs..  100. 2004
• Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood..  98. 2003
• Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma..  98. 2003
• Cytologic features of the nested variant of urothelial carcinoma: a study of seven cases..  99. 2003
• Intra-abdominal fibrosis after systemic and intraperitoneal therapy containing fluoropyrimidines..  88. 2000
• Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma..  86. 1999
• 5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma..  86. 1999
• Listeriosis in pediatric oncology patients..  83. 1998
• Prognostic risk factors in low stage testicular germ cell tumors: unanswered questions regarding clinically useful prognosticators for extratesticular disease..  82. 1998
• Neutropenic enterocolitis in a patient with colorectal carcinoma: unusual course after treatment with 5-fluorouracil and leucovorin--a case report..  80. 1997
• Acute pancreatitis associated with continuous infusion cytarabine therapy: a case report..  77. 1996
• Malignant mesenchymoma..  77. 1996
• Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level..  76. 1995
• Clonal changes in inflammatory pseudotumor of the lung: a case report..  76. 1995
• Autologous bone marrow transplantation in children with advanced neuroblastoma..  76. 1995
• Molecular genetic analysis demonstrates that multiple posttransplantation lymphoproliferative disorders occurring in one anatomic site in a single patient represent distinct primary lymphoid neoplasms..  75. 1995
• Transient, severe hyperlipidemia in patients with acute lymphoblastic leukemia treated with prednisone and asparaginase..  74. 1994
• Hormonal ablation as effective therapy for carcinomatous meningitis from prostatic carcinoma..  73. 1994
• Mesenchymal chondrosarcoma of the orbit. Report of three new cases and review of the literature..  73. 1994
• Collision of transitional cell carcinoma and renal cell carcinoma. An immunohistochemical study and review of the literature..  73. 1994
• Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy..  72. 1993
• Treatment-related esophageal stricture in pediatric patients with cancer..  71. 1993
• Epithelioid osteosarcoma of bone. Immunocytochemical evidence suggesting divergent epithelial and mesenchymal differentiation in a primary osseous neoplasm..  71. 1993
• Immune-mediated thrombocytopenia secondary to suramin..  71. 1993
• Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor. A possible new recombinant granulocyte colony-stimulating factor toxicity..  70. 1992
• Necrotizing pneumonitis caused by 5-fluorouracil infusion. A complication of a Hickman catheter..  70. 1992
• T-cell chronic lymphocytic leukemia. Unusual morphologic, phenotypic, and karyotypic features in association with light chain amyloidosis..  70. 1992
• Extraneural metastases of infratentorial glioblastoma multiforme to the peritoneal cavity..  69. 1992
• Production of granulocyte-macrophage colony-stimulating factor in two patients with lung cancer, leukocytosis, and eosinophilia..  69. 1992
• Type Ia glycogenosis associated with hepatocellular carcinoma..  69. 1992
• Turcot's syndrome. Flow cytometric analysis..  68. 1991
• The malignant nature of papillary and cystic neoplasm of the pancreas..  68. 1991
• Intracerebral Hodgkin's disease in a human immunodeficiency virus-seropositive patient..  67. 1991
• Primary central nervous system lymphoma as a secondary malignancy..  67. 1991
• Massive pulmonary hemangiopericytoma. An innovative approach to evaluation and treatment..  64. 1989
• Carboplatin-associated thrombotic microangiopathic hemolytic anemia..  64. 1989
• Diffuse cystic angiomatosis of the breast..  62. 1988
• The association of progressive, atrophying, chronic, granulomatous dermohypodermitis with Hodgkin's disease..  62. 1988
• Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil..  62. 1988
• Radiation-induced angiosarcoma..  60. 1987
• Megakaryoblastic transformation of chronic granulocytic leukemia..  60. 1987
• A complication of prolonged infusional chemotherapy masquerading as a bone metastasis in a patient with colorectal carcinoma..  59. 1987
• Lymphangiosarcoma associated with chronic filarial lymphedema..  59. 1987
• Monitoring intravesical bacillus Calmette-Guerin treatment of superficial bladder carcinoma by serial flow cytometry..  58. 1986
• Intrapulmonary presentation of extraskeletal myxoid chondrosarcoma of the extremity. Report of two cases..  58. 1986
• Chronic renal failure: a significant risk factor in the development of acquired renal cysts and renal cell carcinoma. Case reports and review of the literature..  57. 1986
• Familial neuroblastoma. Case reports, literature review, and etiologic considerations..  57. 1986
• Consecutive lymphoma with monoclonal gammopathy in a married couple..  57. 1986
• Non-Hodgkin's lymphoma associated with pregnancy. A report of six cases, with a review of the literature..  56. 1985
• Teratoma with malignant transformation in germ cell tumors in men..  56. 1985
• Bowel perforation during initial treatment for childhood non-Hodgkin's lymphoma..  56. 1985
• A distinctive cutaneous malignant neoplasm expressing the Langerhans cell phenotype. Synchronous occurrence with B-chronic lymphocytic leukemia..  55. 1985
• Endoscopic diagnosis and treatment of upper-tract urothelial tumors. A preliminary report..  55. 1985
• Multiple nevoid basal cell carcinoma syndrome and Hodgkin's disease..  53. 1984
• Primary hepatic or hepatosplenic non-Hodgkin's lymphoma in children..  52. 1983
• Proliferative myositis of the masseter muscle. A case report and a review of the literature..  52. 1983
• Acute myocardial infarction with normal coronary arteriogram after mantle field radiation therapy for Hodgkin's disease..  52. 1983
• Plasmapheresis in a patient with angioimmunoblastic lymphadenopathy. Improvement in clinical and immunologic abnormalities..  51. 1983
• Granulomatous infections complicating hairy cell leukemia..  49. 1982
• Splenic rupture in patients with hematologic malignancies..  48. 1981
• Malignant thymoma: renal metastases responding to cis-platinum..  48. 1981
• Combined Pneumocystis carinii and Nocardia asteroides pneumonitis in a patient with an ACTH-producing carcinoid..  47. 1981
• Unusual presentation of bronchogenic carcinoma: case report and review of the literature..  47. 1981
• Spontaneous regression of pulmonary metastases from transitional cell carcinoma..  46. 1980
• Phase II trial of neocarzinostatin in patients with bladder and prostatic cancer: toxicity of a five-day iv bolus schedule..  45. 1980
• Bone marrow transplantation for the therapy of refractory adult T cell acute lymphoblastic leukemia..  45. 1980
• Small-cell carcinoma of the esophagus: treatment by chemotherapy alone..  45. 1980
• Acclerated growth of testicular cancer after cytoreductive surgery..  45. 1980
• Surgical repair of esophagobronchial fistula following successful treatment of Hodgkin's disease..  44. 1979
• Philadelphia chromosome positive chronic myelogenous leukemia developing in a patient with acute lymphoblastic leukemia..  43. 1979
• Factors associated with prolonged survival in chronic myeloid leukemia..  42. 1978
• Immunoblastic lymphadenopathy and adenocarcinoma of the pancreas: a case report..  42. 1978
• Iatrogenic lactic acidosis: association with hypertonic glucose administration in a patient with cancer..  42. 1978
• Incidental discovery at radical mastectomy of inapparent Hodgkin's disease in long term survivors..  42. 1978
• Hodgkin's disease and granulomatous angiitis of the central nervous system..  38. 1976
• Methotrexate pneumonitis induced by intrathecal methotrexate therapy: a case report with pharmacokinetic data..  38. 1976
• Thymoma and chronic myelogenous leukemia: a case report..  38. 1976
• Long-term effects on external radiation on the pituitary and thyroid glands..  37. 1976
• Acute leukemia presenting as laryngeal obstruction..  34. 1974
• Thinking ahead: Neurocognition and diabetes in long-term pediatric cancer survivors..  131. 2025
• Shedding LIGHT on the changing landscape of poly-ADP ribose polymerase inhibitors in ovarian cancer..  131. 2025
• The need for multilevel supportive care infrastructure for cancer caregivers..  130. 2024
• Let's ask the patient: Self-reported quality-of-life measures help to predict kidney cancer mortality..  128. 2021
• Young adult caregivers' perceptions of cancer misinformation on social media: Response to Warner et al..  127. 2020
• Nasopharynx cancer: Induction or adjuvant? That is the question..  126. 2020
• Improving therapy for patients with epidermal growth factor receptor-mutant lung cancer..  124. 2018
• Running the marathon of chronic myeloid leukemia with no shoes (or without the right shoes)!.  123. 2017
• Missing the mark in FGFR1-amplified squamous cell cancer of the lung..  122. 2016
• Specialty care for adult survivors of childhood cancer..  121. 2015
• Notch inhibition in desmoids: "Sure it works in practice, but does it work in theory?"..  121. 2015
• Inherited predisposition to endometrial cancer: moving beyond Lynch syndrome..  121. 2014
• Quality lung cancer screening protects quality of life: no harm, no foul..  120. 2014
• Translational immunotherapeutics: chemoimmunotherapy for malignant pleural mesothelioma..  120. 2014
• Preoperative chemotherapy for bladder cancer: a standard waits to be optimally deployed..  118. 2011
• Technology impacting on biology: spine radiosurgery..  117. 2011
• Proceedings of the First International Inflammatory Breast Cancer Conference..  116. 2010
• High-risk, high-grade (T1G3) bladder cancer: models versus reality..  115. 2009
• The 2008 European School of Oncology inside track conference, "predictive modeling in prostate cancer"..  115. 2009
• The "microscopic" revolution in breast carcinoma..  103. 2005
• Seeking the solution to the problem of metastatic renal carcinoma..  97. 2003
• Agonizing over AGUS..  87. 1999
• Progression of T1 bladder tumors: better staging or better biology?.  86. 1999
• Hepatocellular carcinoma and coinfection with hepatitis B and C. Making a difficult situation worse..  86. 1999
• Understanding ductal carcinoma in situ: a step in the right direction..  86. 1999
• Economic analysis of expensive technologies: the case of erythropoietin..  83. 1998
• Detectable tumor cells in the blood and bone marrow: smoke or fire?.  83. 1998
• The natural history of clinical prostate carcinoma..  80. 1997
• BRCA1. A new marker in the management of patients with breast cancer?.  77. 1996
• The natural history of ductal carcinoma in situ. Implications for clinical decision making..  76. 1995
• Optimal treatment for advanced seminoma?.  72. 1993
• Radical surgery for gastric cancer. A review of the Japanese experience..  64. 1989
• Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025. 2026
• Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment Consortium. 2025
• Gender equity gap persists, addressing the root cause through the lens of gynecologic oncology: An evidenced-based review. 2025
• Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024. 2024
• Defining disease modification in myelofibrosis in the era of targeted therapy. 2022
• Cancer-related inflammation and depressive symptoms: Systematic review and meta-analysis. 2022
• Improving the quality of care for patients with advanced epithelial ovarian cancer: Program components, implementation barriers, and recommendations. 2021
• Blood-based biomarkers of human papillomavirus-associated cancers: A systematic review and meta-analysis. 2020
• The METeoric rise of MET in lung cancer. 2020
• The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. 2020
• Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population? 2019
• Effects of psychosocial interventions on meaning and purpose in adults with cancer: A systematic review and meta-analysis. 2019
• Androgen-deprivation therapy, dementia, and cognitive dysfunction in men with prostate cancer: How much smoke and how much fire? 2018
• Risk-reducing salpingectomy: Let us be opportunistic. 2017
• Current management and future directions in metastatic pancreatic adenocarcinoma. 2016
• Irradiation and immunotherapy: From concept to the clinic. 2016
• Social well-being among adolescents and young adults with cancer: A systematic review. 2016
• New York Citywide Colon Cancer Control Coalition: A public health effort to increase colon cancer screening and address health disparities. 2015
• Immunotherapy in hepatocellular carcinoma: Primed to make a difference? 2015
• Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. 2015
• Small cell lung cancer: where do we go from here? 2014
• Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date. 2014
• Novel endoscopic diagnosis for bladder cancer. 2014
• Treating advanced hepatocellular carcinoma: How to get out of first gear. 2014
• Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature. 2012
• Practical management of patients with chronic myeloid leukemia. 2011
• Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications. 2010
• Killing tumor cells through their surface beta(2)-microglobulin or major histocompatibility complex class I molecules. 2010
• Locoregional treatment of primary breast cancer: consensus recommendations from an International Expert Panel. 2010
• Nomograms for staging, prognosis, and predicting treatment outcomes. 2009
• Meta-analysis of sentinel lymph node positivity in thin melanoma ( 2009
• Cancer screening and aging: research barriers and opportunities. 2008
• An updated catalog of prostate cancer predictive tools. 2008
• Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. 2008
• Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting. 2008
• Cognitive effects of hormone therapy in men with prostate cancer: a review. 2008
• Manipulating the chemokine-chemokine receptor network to treat cancer. 2007
• Proceedings of the Consensus Conference on Breast Conservation, April 28 to May 1, 2005, Milan, Italy. 2006
• Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania. 2004
• Overview of bladder cancer trials in the Cancer and Leukemia Group B. 2003
• Prostate carcinoma: defining therapeutic objectives and improving overall outcomes. 2003
• RANK-Fc: a therapeutic antagonist for RANK-L in myeloma. 2003
• Ductal lavage and the clinical management of women at high risk for breast carcinoma: a commentary. 2002
• Rehabilitation of persons with central nervous system tumors. 2001
• Strategies for managing cancer-related fatigue syndrome: a rehabilitation approach. 2001
• Neuroblastoma metastatic to the central nervous system. The Memorial Sloan-kettering Cancer Center Experience and A Literature Review. 2001
• Therapeutic choices in younger patients with chronic myelogenous leukemia. 2000
• Novel strategies and therapeutics for the treatment of prostate carcinoma. 2000
• Complications of bone metastases: surgical management. 2000
• Consensus Conference on the Treatment of In Situ Ductal Carcinoma of the Breast, April 22-25, 1999. 2000
• The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature. 1999
• Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse--the Children's Cancer Group Experience. 1998
• Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. 1997
• Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin. 1996
• Depression in patients with pancreatic carcinoma. Diagnostic and treatment issues. 1996
• Selection criteria for breast conservation. The impact of young and old age and collagen vascular disease. 1994
• Overview of clinical radioimmunodetection of human tumors. 1994
• Enhancing the effectiveness of the specific serotonin antagonists. Combination antiemetic therapy with dexamethasone. 1993
• Localized carcinoma of the prostate (stages T1B, T1C, T2, and T3). Review of management with external beam radiation therapy. 1993
• Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. 1993
• Imaging in gynecologic malignancies. 1993
• Intraperitoneal chemotherapy in the management of ovarian cancer. 1993
• Transgenic models for the study of prostate cancer. 1993
• Recent advances in the treatment of advanced colorectal cancer. 1993
• Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis. 1992
• The association of benign prostatic hyperplasia and cancer of the prostate. 1992
• Carcinoma of the female reproductive organs. Value of cross-sectional imaging. 1991
• Radioimmunology. Imaging and therapy. 1991
• A meta-analysis of stages I and II Hodgkin's disease. 1990
• Stereotaxic irradiation of brain tumors. 1990
• Radical surgery for gastric cancer. A review of the Japanese experience. 1989
• Psychiatric management of cancer pain. 1989
• Reduced incidence of the somnolence syndrome in leukemic children with steroid coverage during prophylactic cranial radiation therapy. Results of a pilot study. 1989
• Advances in imaging. 1988
• Second malignancies after childhood Hodgkin's disease. The Memorial Sloan-Kettering Cancer Center experience. 1988
• State of the art in comparative cancer clinical trials. 1987
• Endodermal sinus tumor of the mediastinum. A report of seven cases and review of the literature. 1986
• Harnessing T-lymphocytes for human cancer immunotherapy. 1985
• Metabolic response to surgery in the cancer patient: consequences of aggressive multimodality therapy. 1979
• Carcinoma arising in a branchial cleft cyst. 1976

Identity

ISO Abbreviation

• Cancer

Linking ISSN

• 0008-543X

International Standard Serial Number (ISSN)

• 0008-543X

Electronic International Standard Serial Number (EISSN)

• 1097-0142